"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOUSSN_VANVITELLI",2000,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2001,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2002,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2003,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2004,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2006,1,4,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,7,0.137044747386565,NA,0,1,0,0,0,0,"ROCCO AVERSA;BENIAMINO DI MARTINO;NICOLA MAZZOCCA;SALVATORE VENTICINQUE","1;1;1;1","ROCCO AVERSA;BENIAMINO DI MARTINO;NICOLA MAZZOCCA;SALVATORE VENTICINQUE","0.25;0.25;0.25;0.25","BENIAMINO DI MARTINO","1","BENIAMINO DI MARTINO","0.25","BENIAMINO DI MARTINO;NICOLA MAZZOCCA;ROCCO AVERSA;SALVATORE VENTICINQUE","7;7;7;7","BENIAMINO DI MARTINO","7","BENIAMINO DI MARTINO","1","COMPUTER SCIENCE","1","COMPUTER NETWORK;WORLD WIDE WEB","1;1","INTEROPERABILITY;MOBILE COMPUTING;MOBILE DEVICE;PERSONALIZATION;WEB SERVICE","1;1;1;1;1","SERVICE DISCOVERY;SERVICE-ORIENTED ARCHITECTURE;SERVICES COMPUTING;WEB DEVELOPMENT","1;1;1;1","WEB APPLICATION SECURITY","1","","1","MOBILE AGENT TECHNOLOGY IN NETWORK MANAGEMENT","1","DYNAMIC SERVICE COMPOSITION;MOBILE AGENTS;SERVICE DISCOVERY;SERVICE-ORIENTED ARCHITECTURE;SERVICE-ORIENTED COMPUTING;SERVICES COMPUTING;WEB SERVICE COMPOSITION;WS-I BASIC PROFILE","1;1;1;1;1;1;1;1","AGENTS BASED;BASED INFRASTRUCTURE;MOBILE AGENTS;SERVICES COMPOSITION;WEB SERVICES","1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2007,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2008,2,3,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0.5,1,0.018224273885007,NA,0,1,0,0,0,0,"ROCCO AVERSA;ANTONIO VIVIANI;BENIAMINO DI MARTINO;C. GOLIA;SALVATORE VENTICINQUE;BERNARDO BUONOMO","1;1;1;1;1;1","ROCCO AVERSA;ANTONIO VIVIANI;BENIAMINO DI MARTINO;C. GOLIA;SALVATORE VENTICINQUE;BERNARDO BUONOMO","0.33;0.33;0.33;0.33;0.33;0.33","BENIAMINO DI MARTINO;BERNARDO BUONOMO","1;1","BENIAMINO DI MARTINO;BERNARDO BUONOMO","0.33;0.33","BENIAMINO DI MARTINO;ROCCO AVERSA;SALVATORE VENTICINQUE;ANTONIO VIVIANI;BERNARDO BUONOMO;C. GOLIA","2;2;2;0;0;0","BENIAMINO DI MARTINO;BERNARDO BUONOMO","2;0","BENIAMINO DI MARTINO;BERNARDO BUONOMO","1;0","ART;BIOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PHYSICS","1;1;1;1;1;1","APPLIED MATHEMATICS;COMBINATORICS;COMPUTER SECURITY;ECONOMY;HUMAN–COMPUTER INTERACTION;INFORMATION RETRIEVAL;MATHEMATICAL ANALYSIS;MULTIMEDIA;OPTICS;PALEONTOLOGY;VISUAL ARTS;WORLD WIDE WEB","1;1;1;1;1;1;1;1;1;1;1;1","ADAPTATION (EYE);ARCHITECTURE;CONTEXT (ARCHAEOLOGY);DIFFERENTIAL OPERATOR;DISCRETIZATION;EXPLOIT;KERNEL (ALGEBRA);LAPLACE OPERATOR;METADATA;PARTIAL DIFFERENTIAL EQUATION;SEMANTIC WEB;SERVICE (BUSINESS);TAYLOR SERIES;UBIQUITOUS COMPUTING;WEB SERVICE;XML","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CONTENT ADAPTATION;LINKED DATA;METADATA REPOSITORY;SEMANTIC WEB STACK","1;1;1;1","META DATA SERVICES","1","","2","SEMANTIC WEB AND ONTOLOGY DEVELOPMENT;TURBULENT INTERACTIONS WITH DISPERSED PARTICLES AND DROPLETS","1;1","AUTOMATED WEB SERVICE DISCOVERY;BINARY FLUID SYSTEMS;CONTENT ADAPTATION;DATA INTEGRATION;DISCRETE PARTICLE SIMULATION;IMMERSED BOUNDARY METHOD;KERNEL (ALGEBRA);LAGRANGIAN SIMULATION;LINKED DATA;SEMANTIC WEB SERVICES;SERVICE-ORIENTED ARCHITECTURE;TWO-PHASE FLOW;WEB SERVICE COMPOSITION","1;1;1;1;1;1;1;1;1;1;1;1;1","ADAPTIVE MULTIMEDIA;BASED INTEGRATED;BLOBS METHOD;BUOYANT FLOW;INTEGRATED ARCHITECTURE;LAGRANGIAN BLOBS;MULTIMEDIA DELIVERY;NUMERICAL SOLUTION;SERVICES BASED;THERMAL BUOYANT","1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,0,0,100,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;2","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1","INFECTION","1","6.1 PHARMACEUTICALS","2","KIDNEY CANCER;LIVER CANCER","1;1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2009,3,4.66666666666667,1,1,0,1,1.5,1.5,0,1.5,0,2,0,0,0,1,0,0,0,0.33,3,0.0648547373983642,NA,0,0.666666666666667,0.46,0.167,0,0.167,"NICOLA DE LUCA;LUDOVICO DOCIMO;F GILIO;FABRIZIO FORONI;ROBERTO RUGGIERO;ADELMO GUBITOSI;GIOVANNI DOCIMO;NICOLA AVENIA;G ISIDE;F A MALINCONICO;LUIGI SPARAVIGNA;M AGRESTI;GIUSI MOCCIA","2;1;1;1;1;1;1;1;1;1;1;1;1","NICOLA DE LUCA;LUDOVICO DOCIMO;F GILIO;FABRIZIO FORONI;ROBERTO RUGGIERO;ADELMO GUBITOSI;GIOVANNI DOCIMO;NICOLA AVENIA;G ISIDE;F A MALINCONICO;LUIGI SPARAVIGNA;M AGRESTI;GIUSI MOCCIA","2;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08","NICOLA DE LUCA;ADELMO GUBITOSI","2;1","NICOLA DE LUCA;ADELMO GUBITOSI","2;0.08","NICOLA DE LUCA;ADELMO GUBITOSI;F A MALINCONICO;F GILIO;FABRIZIO FORONI;G ISIDE;GIOVANNI DOCIMO;GIUSI MOCCIA;LUDOVICO DOCIMO;LUIGI SPARAVIGNA;M AGRESTI;NICOLA AVENIA;ROBERTO RUGGIERO","7;2;2;2;2;2;2;2;2;2;2;2;2","NICOLA DE LUCA;ADELMO GUBITOSI","7;2","NICOLA DE LUCA;ADELMO GUBITOSI","2;1","BUSINESS;ECONOMICS;POLITICAL SCIENCE;BIOLOGY;CHEMISTRY;HISTORY;MEDICINE","2;2;2;1;1;1;1","FINANCE;LAW;LAW AND ECONOMICS;MARKET ECONOMY;ARCHAEOLOGY;CELL BIOLOGY;IMMUNOLOGY;ORGANIC CHEMISTRY;PUBLIC ECONOMICS;SURGERY","2;2;2;2;1;1;1;1;1;1","BANKRUPTCY;CAPITAL (ARCHITECTURE);CORPORATE GOVERNANCE;DEBT;EXTRACELLULAR MATRIX;FIBRIN;FIBRIN GLUE;FISTULA;INCENTIVE;INSOLVENCY;NEGOTIATION;ORDER (EXCHANGE);POLITICS;SEALANT;WELFARE;WOUND HEALING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANAL FISTULA;CREDITOR;FIBRIN TISSUE ADHESIVE;OPPRESSION;SHAREHOLDER","1;1;1;1;1","DEBTOR","1","COLLAGEN;;FIBRIN TISSUE ADHESIVE;RECTAL FISTULA;TISSUE ADHESIVES;ABSORBABLE IMPLANTS;AGED;ANIMALS;EXTRACELLULAR MATRIX;FEMALE;HORSES;HUMANS;MALE;MIDDLE AGED;RECURRENCE;RETROSPECTIVE STUDIES;SWINE","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ANORECTAL SURGICAL PROCEDURES;GLOBAL BANKRUPTCY LAW AND FINANCIAL DISTRESS;REGULATORY COMPETITION IN EUROPEAN COMPANY LAW","1;1;1","ANAL FISTULA PLUG;BANKRUPTCY LAW;CAPITAL (ARCHITECTURE);CORPORATE LAW ARBITRAGE;DEBTOR;FIBRIN GLUE TREATMENT;FIBRIN TISSUE ADHESIVE;FISTULAS;LIGATION OF INTERSPHINCTERIC FISTULA TRACT;OPPRESSION","1;1;1;1;1;1;1;1;1;1","ANAL FISTULA;BANKRUPTCY REORGANIZATION;COLLAGENIC PLUG;CONSERVATIVE ANAL;CURE RE-ORGANIZING;FIBRIN SEALANT;FISTULA TREATMENT;GROWTH FAIRNESS;HUMAN FIBRIN;PRECISE EQUALITY;PRELIMINARY RESULTS;SEALANT PRELIMINARY;SHAREHOLDERS WELFARE;UNEQUAL TREATMENT;WELFARE GROWTH","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,5,65,100,1,0.5,12.5,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","2;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LUNG;MUSCULAR DYSTROPHY;PEDIATRIC;RARE DISEASES","1;1;1;1;1;1;1;1;1","NEUROLOGICAL;RESPIRATORY","1;1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2010,3,1,1,1,0,1,3,3,0,3,0,3,0,0,0,0,0,0,0,0,1,0.0221284988715517,NA,0,1,0,0,0,0,"NICOLA DE LUCA","3","NICOLA DE LUCA","3","NICOLA DE LUCA","3","NICOLA DE LUCA","3","NICOLA DE LUCA","3","NICOLA DE LUCA","3","NICOLA DE LUCA","3","BUSINESS;ECONOMICS;POLITICAL SCIENCE;COMPUTER SCIENCE;HISTORY","3;3;3;1;1","LAW;ACCOUNTING;FINANCE;LAW AND ECONOMICS;MARKET ECONOMY;ARCHAEOLOGY;ARTIFICIAL INTELLIGENCE;MONETARY ECONOMICS;PROGRAMMING LANGUAGE","3;2;2;2;2;1;1;1;1","CORPORATE GOVERNANCE;CAPITAL (ARCHITECTURE);CORPORATION;DEBT;DECREE;DIRECTIVE;DIVIDEND;HUMAN CAPITAL;INCENTIVE;LEGISLATURE;PARAGRAPH;PERSPECTIVE (GRAPHICAL);POLITICS;TAX REFORM","2;1;1;1;1;1;1;1;1;1;1;1;1;1","SHAREHOLDER;CAPITAL REQUIREMENT;CORPORATE LAW;CREDITOR;DIVIDEND POLICY;FINANCIAL CAPITAL;STATE INCOME TAX;VOTING","2;1;1;1;1;1;1;1","GROSS INCOME","1","","3","REGULATORY COMPETITION IN EUROPEAN COMPANY LAW;DEVELOPMENT AND HARMONIZATION OF EUROPEAN PRIVATE LAW","2;1","CAPITAL (ARCHITECTURE);CORPORATION;DECREE;DIRECTIVE;DIVIDEND POLICY;DIVIDEND TAX;EUROPEAN COMPANY LAW;PARAGRAPH;PROPERTY RIGHTS","1;1;1;1;1;1;1;1;1","CAPITAL MAINTENANCE;COMPARATIVE OVERVIEW;DATE EMPTY;DIRECTIVE CE;EMPTY VOTING;EQUAL TREATMENT;EU DIRECTIVE;EU LAW;EUROPEAN PERSPECTIVE;EXISTING EU;FINANCIAL MARKETS;HIDDEN OWNERSHIP;LAW PROTECT;RECORD DATE","1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,10,4501,200,0,0,87,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,2,0,0,1,1,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","2;1;1","AUTOIMMUNE DISEASE;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;KIDNEY DISEASE","1;1;1;1;1","METABOLIC AND ENDOCRINE","1","6.1 PHARMACEUTICALS","1","NOT SITE-SPECIFIC CANCER","1","6.2 SURVEILLANCE","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2011,1,26,2,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0.0235104446563231,NA,1,1,0,0,0,0,"JOHANNA MYRZIK;MILDE MARIA DA SILVA LIRA;P.J.M. HESKES;S. KONIG;V. ĆUK;LIEVEN VANDEVELDE;A. TESTA;ANTJE ORTHS;MATT R. BOHM;A. L. Z. GRANDI;JAN DESMET;ROBERTO LANGELLA;D. PREIS;PETER SCHEGNER;PAULO F. RIBEIRO;JOSÉ RUBENS MACEDO;BART VERHELST;J. MEYER;ROELOF BERNARDUS TIMENS;COLIN DEBRUYNE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","JOHANNA MYRZIK;MILDE MARIA DA SILVA LIRA;P.J.M. HESKES;S. KONIG;V. ĆUK;LIEVEN VANDEVELDE;A. TESTA;ANTJE ORTHS;MATT R. BOHM;A. L. Z. GRANDI;JAN DESMET;ROBERTO LANGELLA;D. PREIS;PETER SCHEGNER;PAULO F. RIBEIRO;JOSÉ RUBENS MACEDO;BART VERHELST;J. MEYER;ROELOF BERNARDUS TIMENS;COLIN DEBRUYNE","0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04","A. TESTA;ROBERTO LANGELLA","1;1","A. TESTA;ROBERTO LANGELLA","0.04;0.04","A. L. Z. GRANDI;A. TESTA;ANTJE ORTHS;BART VERHELST;COLIN DEBRUYNE;D. PREIS;J. J. A. L. LEITAO;J. MEYER;J.F.G. COBBEN;JAN DESMET;JOHANN JÄGER;JOHANNA MYRZIK;JOSÉ MARÍA ROMERO GORDON;JOSÉ RUBENS MACEDO;LIEVEN VANDEVELDE;MATT R. BOHM;MILDE MARIA DA SILVA LIRA;N. BROWNE;P.J.M. HESKES;PAULO F. RIBEIRO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","A. TESTA;ROBERTO LANGELLA","1;1","A. TESTA;ROBERTO LANGELLA","1;1","COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHILOSOPHY;PHYSICS","1;1;1;1;1","AUTOMOTIVE ENGINEERING;ELECTRICAL ENGINEERING;EPISTEMOLOGY;MATHEMATICAL ANALYSIS;QUANTUM MECHANICS","1;1;1;1;1","POWER (PHYSICS);QUALITY (PHILOSOPHY);VARIABLE (MATHEMATICS);VOLTAGE","1;1;1;1","ELECTRIC POWER SYSTEM;POWER QUALITY","1;1","POWER NETWORK","1","","1","POWER QUALITY ANALYSIS AND MITIGATION TECHNIQUES","1","POWER NETWORK;POWER QUALITY","1;1","DISTRIBUTED GENERATION;ISSUES RELATED;POWER QUALITY;QUALITY ISSUES","1;1;1;1","APPLIANCES COMPUTERS;COMPUTERS DATA;CURRENT EMISSIONS;DATA PROCESSING;DECADES PQ;DRIVES ELECTRONIC;ELECTRONIC APPLIANCES;ELECTRONIC BALLASTS;EQUIPMENTS VARIABLE;INCREASED ENORMOUSLY;NETWORK VOLTAGE;NON-LINEAR OPERATING;OPERATING CHARACTERISTICS;PQ RELATED;PROCESSING EQUIPMENTS;PRODUCE CURRENT;SPEED DRIVES;SUPPLY VOLTAGE;VARIABLE SPEED;VOLTAGE DISTURBANCES","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,50,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1",NA,NA,"INFECTION","1",NA,NA,"STOMACH CANCER","1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2012,1,1,1,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"NICOLA DE LUCA","1","NICOLA DE LUCA","1","NICOLA DE LUCA","1","NICOLA DE LUCA","1","NICOLA DE LUCA","0","NICOLA DE LUCA","0","NICOLA DE LUCA","0","BUSINESS;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE","1;1;1;1","ACCOUNTING;FINANCE;LAW;LAW AND ECONOMICS;PROGRAMMING LANGUAGE","1;1;1;1;1","CAPITAL MARKET;CORPORATE GOVERNANCE;CORPORATION;DEBT;DIRECTIVE;ISSUER;LEGISLATION","1;1;1;1;1;1;1","CORPORATE LAW;CREDITOR;SHAREHOLDER","1;1;1","SHARE CAPITAL;TENDER OFFER","1;1","","1","REGULATORY COMPETITION IN EUROPEAN COMPANY LAW","1","CORPORATION;DIRECTIVE;EUROPEAN COMPANY LAW;ISSUER;SHARE CAPITAL;TENDER OFFER","1;1;1;1;1;1","","","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2013,3,5,1.33333333333333,0.333333333333333,0.333333333333333,0.333333333333333,1,0.5,0.5,0.5,0,1,0,0,0,2,0,0,0,0.67,7,0.200615806321402,1,0,1,0.45,0,0,0,"SALVATORE CURCIO;M. FIORETTO;PATRIZIO MANGANIELLO;G. PETRONE;NICOLA DE LUCA;M. VITELLI;L. FEOLA;PIETRO LUIGI CAROTENUTO;GUIDO RUBINO;LUIGI RUBINO;ROBERTO LANGELLA;G. SPAGNUOLO;A. TESTA;P. MARINO;N. SERBIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NICOLA DE LUCA;SALVATORE CURCIO;PATRIZIO MANGANIELLO;G. PETRONE;M. VITELLI;PIETRO LUIGI CAROTENUTO;G. SPAGNUOLO;M. FIORETTO;L. FEOLA;GUIDO RUBINO;LUIGI RUBINO;ROBERTO LANGELLA;A. TESTA;P. MARINO;N. SERBIA","1;0.17;0.17;0.17;0.17;0.17;0.17;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12","PATRIZIO MANGANIELLO;NICOLA DE LUCA;M. VITELLI;N. SERBIA","1;1;1;1","NICOLA DE LUCA;PATRIZIO MANGANIELLO;M. VITELLI;N. SERBIA","1;0.17;0.17;0.12","G. PETRONE;G. SPAGNUOLO;M. VITELLI;PATRIZIO MANGANIELLO;PIETRO LUIGI CAROTENUTO;SALVATORE CURCIO;A. TESTA;GUIDO RUBINO;L. FEOLA;LUIGI RUBINO;M. FIORETTO;N. SERBIA;P. MARINO;ROBERTO LANGELLA;NICOLA DE LUCA","17;17;17;17;17;17;4;4;4;4;4;4;4;4;0","M. VITELLI;PATRIZIO MANGANIELLO;N. SERBIA;NICOLA DE LUCA","17;17;4;0","M. VITELLI;N. SERBIA;PATRIZIO MANGANIELLO;NICOLA DE LUCA","1;1;1;0","COMPUTER SCIENCE;MATHEMATICS;BUSINESS;ECONOMICS;ENGINEERING;GEOGRAPHY;SOCIOLOGY","2;2;1;1;1;1;1","ALGORITHM;ARTIFICIAL INTELLIGENCE;CONTROL ENGINEERING;ECONOMIC POLICY;ECONOMIC SYSTEM;ELECTRICAL ENGINEERING;ELECTRONIC ENGINEERING;EMBEDDED SYSTEM;GEOMETRY;REGIONAL SCIENCE;SOCIAL SCIENCE;STATISTICS","2;1;1;1;1;1;1;1;1;1;1;1","AGENCY (PHILOSOPHY);CONTROL (MANAGEMENT);CONTROL RECONFIGURATION;FEDERAL STATE;GRID;RUSSIAN ECONOMY;STATE (COMPUTER SCIENCE);STATISTIC;VOLTAGE","1;1;1;1;1;1;1;1;1","AC POWER;CONTROL THEORY (SOCIOLOGY);CONVERTERS;DISTRIBUTION GRID;TRANSFORMER","1;1;1;1;1","DISTRIBUTION TRANSFORMER","1","","3","CONTROL AND SYNCHRONIZATION IN MICROGRID SYSTEMS;GOVERNANCE OF COOPERATIVES AND MUTUAL ASSOCIATIONS;PHOTOVOLTAIC MAXIMUM POWER POINT TRACKING TECHNIQUES","1;1;1","CONCENTRATOR PHOTOVOLTAICS;CONTROL RECONFIGURATION;COOPERATIVES;DISTRIBUTION GRID;FEDERAL STATE;INVERTER-BASED DGS;MICROGRID CONTROL;MODULAR MULTILEVEL CONVERTERS;MPPT TECHNIQUES;PARAMETER ESTIMATION;PHOTOVOLTAIC ARRAYS;PV SYSTEM;STATISTIC;VOLTAGE SOURCE CONVERTERS","1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANCILLARY SERVICES;DISTRIBUTION NETWORKS;DYNAMICAL RECONFIGURATION;MV DISTRIBUTION;PV ARRAYS","1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2014,4,7.75,2.25,0.5,0,0.5,1.28571428571429,0.666666666666667,0,0.666666666666667,0,0,0,1,0,3,0,0.25,0,0.75,9.5,0.25137794092744,1.5,0,1,0.238,0.167,0,0.167,"MARIO LUISO;CARMINE LANDI;DANIELE GALLO;LORENZO MARINELLI;FERDINANDO RICCARDI;SAVERIO CINIERI;FERDINANDO DE VITA;SALVATORE PISCONTI;GIANFRANCO FILIPPELLI;EVARISTO MAIELLO;A. ROSANO;PALMA FEDELE;SANDRO BARNI;GIUSEPPE COLUCCI;GIANLUCA AURILIO;ORONZIO MANCA;BERNARDO BUONOMO;LIVIO BLASI;FRANCESCO VERDERAME;GIORGIO GRADITI","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MARIO LUISO;CARMINE LANDI;DANIELE GALLO;LORENZO MARINELLI;ORONZIO MANCA;BERNARDO BUONOMO;SERGIO NARDINI;GIANLUCA AURILIO;GIORGIO GRADITI;A. ROSANO;VINCENZO PACIELLO;MARCO LANDI;FERDINANDO RICCARDI;SAVERIO CINIERI;FERDINANDO DE VITA;SALVATORE PISCONTI;GIANFRANCO FILIPPELLI;EVARISTO MAIELLO;PALMA FEDELE;SANDRO BARNI","0.37;0.37;0.37;0.25;0.25;0.25;0.25;0.2;0.2;0.17;0.17;0.17;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06","MARIO LUISO;CARMINE LANDI;DANIELE GALLO;FERDINANDO DE VITA;A. ROSANO;GIANLUCA AURILIO;ORONZIO MANCA","2;2;2;1;1;1;1","MARIO LUISO;CARMINE LANDI;DANIELE GALLO;ORONZIO MANCA;GIANLUCA AURILIO;A. ROSANO;FERDINANDO DE VITA","0.37;0.37;0.37;0.25;0.2;0.17;0.06","CARMINE LANDI;DANIELE GALLO;MARIO LUISO;GIANLUCA AURILIO;GIORGIO GRADITI;A. ROSANO;MARCO LANDI;VINCENZO PACIELLO;EVARISTO MAIELLO;FERDINANDO DE VITA;FERDINANDO RICCARDI;FRANCESCO GIOTTA;FRANCESCO VERDERAME;GIANFRANCO FILIPPELLI;GIOVANNI PAPPAGALLO;GIUSEPPE COLUCCI;LAURA ORLANDO;LIVIO BLASI;NICOLA GEBBIA;PALMA FEDELE","33;33;33;23;23;10;10;10;3;3;3;3;3;3;3;3;3;3;3;3","DANIELE GALLO;MARIO LUISO;CARMINE LANDI;GIANLUCA AURILIO;A. ROSANO;FERDINANDO DE VITA;ORONZIO MANCA","33;33;23;23;10;3;2","DANIELE GALLO;MARIO LUISO;A. ROSANO;CARMINE LANDI;FERDINANDO DE VITA;GIANLUCA AURILIO;ORONZIO MANCA","2;2;1;1;1;1;1","PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MEDICINE","3;2;2;2;1","QUANTUM MECHANICS;COMPOSITE MATERIAL;COMPUTER NETWORK;ELECTRICAL ENGINEERING;EMBEDDED SYSTEM;INTERNAL MEDICINE;MECHANICS;NANOTECHNOLOGY;ONCOLOGY;RELIABILITY ENGINEERING","2;1;1;1;1;1;1;1;1;1","POWER (PHYSICS);ALUMINIUM;CANCER;CHARACTERIZATION (MATERIALS SCIENCE);CONVECTION;ENERGY CONSUMPTION;SMART GRID","2;1;1;1;1;1;1","BATTERY (ELECTRICITY);BREAST CANCER;DOCETAXEL;GEMCITABINE;METAL FOAM;POWER-LINE COMMUNICATION;SMART METER","1;1;1;1;1;1;1","METASTATIC BREAST CANCER;TRASTUZUMAB","1;1",";BREAST NEOPLASMS;DEOXYCYTIDINE;ANTIBODIES, MONOCLONAL, HUMANIZED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RECEPTOR, ERBB-2;TAXOIDS;ADULT;AGED;DISEASE-FREE SURVIVAL;DOCETAXEL;FEMALE;HUMANS;MIDDLE AGED;NEOPLASM METASTASIS;TRASTUZUMAB","3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","HER2 SIGNALING IN BREAST CANCER TREATMENT;LITHIUM-ION BATTERY MANAGEMENT IN ELECTRIC VEHICLES;SECURITY CHALLENGES IN SMART GRID SYSTEMS;SOLAR AIR HEATER HEAT TRANSFER ANALYSIS","1;1;1;1","BATTERY MANAGEMENT SYSTEMS;BATTERY TECHNOLOGY;BREAST CANCER;CHARACTERIZATION (MATERIALS SCIENCE);CONVECTION;CONVECTIVE TRANSPORT;ENERGY MANAGEMENT;EXPERIMENTAL INVESTIGATION;HEAT TRANSFER;HER2;LOAD CONTROL;METAL FOAMS;METASTATIC BREAST CANCER;POWER-LINE COMMUNICATION;SMART HOMES;SMART METER;TRASTUZUMAB","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALUMINIUM FOAM;BATTERY CHARACTERIZATION;BIWEEKLY COMBINATION;BREAST CANCER;CANCER RESULTS;CHANNELS HEATED;COST SMART;EXPERIMENTAL INVESTIGATION;GOIM STUDY;HER-POSITIVE METASTATIC;HORIZONTAL CHANNELS;II GOIM;LOW COST;METASTATIC BREAST;METER NETWORK;MIXED CONVECTION;PARTIALLY FILLED;PHASE II;SMART METER;SMART UTILITY;TESTING PROTOCOLS;TRASTUZUMAB DOCETAXEL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2015,6,3.5,1,0.166666666666667,0.166666666666667,0.166666666666667,2,0.5,0.5,0.5,0,0,0,0,1,4,0,0,0.17,0.67,3,0.0804975653792145,3.33333333333333,0.333333333333333,1,0.242,0,0,0,"ORONZIO MANCA;BERNARDO BUONOMO;SALVATORE TAMBURRINO;ASSUNTA ANDREOZZI;HASAN ÇELIK;NICOLA DE LUCA;M. VITELLI;MOGHTADA MOBEDI;LUIGI COSTANZO;BENJAMIN BUTTON-STEPHENS;MARCO BALATO;SERGIO NARDINI","4;4;3;2;1;1;1;1;1;1;1;1","ORONZIO MANCA;BERNARDO BUONOMO;SALVATORE TAMBURRINO;ASSUNTA ANDREOZZI;NICOLA DE LUCA;BENJAMIN BUTTON-STEPHENS;M. VITELLI;LUIGI COSTANZO;MARCO BALATO;HASAN ÇELIK;MOGHTADA MOBEDI;SERGIO NARDINI","1;1;0.75;0.5;0.5;0.5;0.33;0.33;0.33;0.25;0.25;0.25","ORONZIO MANCA;NICOLA DE LUCA;MARCO BALATO","4;1;1","ORONZIO MANCA;NICOLA DE LUCA;MARCO BALATO","1;0.5;0.33","LUIGI COSTANZO;M. VITELLI;MARCO BALATO;ASSUNTA ANDREOZZI;BERNARDO BUONOMO;ORONZIO MANCA;SALVATORE TAMBURRINO;BENJAMIN BUTTON-STEPHENS;HASAN ÇELIK;MOGHTADA MOBEDI;NICOLA DE LUCA;SERGIO NARDINI","12;12;12;6;6;6;6;0;0;0;0;0","MARCO BALATO;ORONZIO MANCA;NICOLA DE LUCA","12;6;0","ORONZIO MANCA;MARCO BALATO;NICOLA DE LUCA","4;1;0","PHYSICS;MATERIALS SCIENCE;COMPUTER SCIENCE;BUSINESS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE","5;4;2;1;1;1;1","MECHANICS;THERMODYNAMICS;COMPOSITE MATERIAL;ACTUARIAL SCIENCE;ARTIFICIAL INTELLIGENCE;ELECTRICAL ENGINEERING;EMBEDDED SYSTEM;LAW;MATHEMATICAL ANALYSIS;MATHEMATICAL OPTIMIZATION;OPERATING SYSTEM;QUANTUM MECHANICS","4;4;2;1;1;1;1;1;1;1;1;1","HEAT TRANSFER;ADIABATIC PROCESS;POROSITY;THERMAL;THERMAL ENERGY STORAGE;TURBULENCE;COMPUTATIONAL FLUID DYNAMICS;CONTROL (MANAGEMENT);CONTROL RECONFIGURATION;CONVECTION;DAMAGES;DIMENSIONLESS QUANTITY;DIODE;HONEYCOMB;INSURANCE POLICY;LAMINAR FLOW;LIFE INSURANCE;LIMIT (MATHEMATICS);MAXIMIZATION;MICROCHANNEL;PHOTOVOLTAIC SYSTEM;POWER (PHYSICS);THERMAL CONDUCTION;THERMAL ENERGY;TOPOLOGY (ELECTRICAL CIRCUITS);TRANSIENT (COMPUTER PROGRAMMING)","4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CONVECTIVE HEAT TRANSFER;HEAT TRANSFER COEFFICIENT;NATURAL CONVECTION;POROUS MEDIUM;REYNOLDS NUMBER;CONTROL THEORY (SOCIOLOGY);FLUENT;FORCED CONVECTION;GENERAL INSURANCE;HEAT FLUX;NANOFLUID;RELIABILITY (SEMICONDUCTOR);RICHARDSON NUMBER;WRONGFUL DEATH","2;2;2;2;2;1;1;1;1;1;1;1;1;1","NUSSELT NUMBER;RAYLEIGH NUMBER;HEAT TRANSFER ENHANCEMENT;INSURANCE LAW","2;2;1;1","","6","HEAT TRANSFER IN POROUS MEDIA AND PACKED BEDS;ECONOMIC ANALYSIS OF LAW AND LEGAL SYSTEMS;HEAT TRANSFER ENHANCEMENT IN NANOFLUIDS;PHOTOVOLTAIC MAXIMUM POWER POINT TRACKING TECHNIQUES","3;1;1;1","HEAT TRANSFER;DARCY NUMBER;BUILDING INTEGRATED PHOTOVOLTAICS;CHURCHILL–BERNSTEIN EQUATION;CONTROL RECONFIGURATION;CONVECTION;CONVECTIVE HEAT TRANSFER;CONVECTIVE TRANSPORT;DIMENSIONLESS QUANTITY;ENERGY CONVERSION EFFICIENCY;FILM TEMPERATURE;FORCED CONVECTION;HEAT AND MASS TRANSFER;HEAT EXCHANGERS;HEAT TRANSFER ENHANCEMENT;HEAT TRANSFER MODELING;HONEYCOMB;LIFE INSURANCE;MAXIMIZATION;MICROCHANNEL","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEAT TRANSFER;PARALLEL SQUARED;TEMPERATURE THERMAL;THERMAL STORAGE;ARRAYS PERFORMANCES;CHANNEL FILLED;CHANNEL SYSTEMS;CONVECTION HEAT;DAMAGES OVERRULING;DYNAMICAL RECONFIGURATION;FORCED CONVECTION;HEATED BLOCKS;INSURANCE LAW;INTERFACIAL HEAT;LIFE DAMAGES;MIXED CONVECTION;MODULES CONNECTIONS;MULTI-OBJECTIVE OPTIMIZATION;NUMERICAL INVESTIGATION;PV ARRAYS;PV MODULES;SECTION MICROCHANNELS;SQUARED CHANNEL;SQUARED CHANNELS;TRANSFER BEHAVIOURS;TRANSFER COEFFICIENT;TRANSIENT ANALYSIS;TRIANGULAR CROSS;UNIFORMLY HEATED;VERTICAL CHANNEL","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,8,33.33,0,0,3,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,NA,NA,"30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","BIOTECHNOLOGY;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;FOOD ALLERGIES;NUTRITION;PEDIATRIC;PREVENTION","1;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM","1",NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2016,3,4,1,1,0,1,3,3,0,3,0,0,0,0,0,3,0,0,0,1,1.67,0.0513088737847478,2.5,0,0.666666666666667,0,0,0,0,"BENIAMINO DI MARTINO;ANTÔNIO ESPÓSITO;ALESSANDRO MARRAZZO;SALVATORE AUGUSTO MAISTO;CAPASSO ANGELO;STEFANIA NACCHIA;SALVATORE D’ANGELO;GIUSEPPINA CRETELLA","3;3;1;1;1;1;1;1","BENIAMINO DI MARTINO;ANTÔNIO ESPÓSITO;GIUSEPPINA CRETELLA;SALVATORE AUGUSTO MAISTO;STEFANIA NACCHIA;ALESSANDRO MARRAZZO;CAPASSO ANGELO;SALVATORE D’ANGELO","0.78;0.78;0.33;0.25;0.25;0.2;0.2;0.2","BENIAMINO DI MARTINO","3","BENIAMINO DI MARTINO","0.78","ANTÔNIO ESPÓSITO;BENIAMINO DI MARTINO;ALESSANDRO MARRAZZO;CAPASSO ANGELO;SALVATORE D’ANGELO;GIUSEPPINA CRETELLA;SALVATORE AUGUSTO MAISTO;STEFANIA NACCHIA","5;5;3;3;3;1;1;1","BENIAMINO DI MARTINO","5","BENIAMINO DI MARTINO","3","COMPUTER SCIENCE;PHILOSOPHY","3;1","PROGRAMMING LANGUAGE;ARTIFICIAL INTELLIGENCE;COMPUTER NETWORK;DISTRIBUTED COMPUTING;EPISTEMOLOGY;HUMAN–COMPUTER INTERACTION;INFORMATION RETRIEVAL;NATURAL LANGUAGE PROCESSING;PARALLEL COMPUTING;SOFTWARE ENGINEERING;TELECOMMUNICATIONS;WORLD WIDE WEB","3;1;1;1;1;1;1;1;1;1;1;1","APPLICATION PROGRAMMING INTERFACE;BUBBLE;HOME AUTOMATION;INTERNET OF THINGS;INTEROPERABILITY;LOGIC PROGRAMMING;MIDDLEWARE (DISTRIBUTED APPLICATIONS);NATURAL LANGUAGE;NEWS AGGREGATOR;ONTOLOGY;PARSING;PROLOG;SEMANTIC WEB;SOFTWARE;WIRELESS SENSOR NETWORK","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTELLIGENT SENSOR;MAXIMUM BUBBLE PRESSURE METHOD;SEMANTIC WEB STACK;SOFTWARE DEVELOPMENT;UNIFIED MODELING LANGUAGE","1;1;1;1;1","APPLICATIONS OF UML;INTERFACE (MATTER);MODEL-DRIVEN ARCHITECTURE;SEMANTIC ANALYTICS;SOFTWARE DEVELOPMENT PROCESS;UML TOOL","1;1;1;1;1;1","","3","ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;SEMANTIC WEB AND ONTOLOGY DEVELOPMENT;WORKFLOW MINING AND BUSINESS PROCESS MANAGEMENT","1;1;1","APPLICATION PROGRAMMING INTERFACE;CONTEXT-AWARE APPLICATIONS;HOME AUTOMATION;INTELLIGENT SENSOR;INTERFACE (MATTER);INTERNET OF THINGS;IOT SECURITY;MOBILE SENSOR DEPLOYMENT;MODEL-DRIVEN ARCHITECTURE;NEWS AGGREGATOR;ONTOLOGY;PROCESS MODELING LANGUAGES;PROCESS MODELS;SEMANTIC BUSINESS PROCESS MANAGEMENT;SEMANTIC MATCHING;SEMANTIC WEB;SEMANTIC WEB SERVICES;WEARABLE SENSORS;WEB SERVICE COMPOSITION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","APPROACH BASED;AUTOMATIC PRODUCTION;BASED APPROACH;BLUEMIX WATSON;BUSINESS PROCESSES;CLOUD APPROACH;IOT FRAMEWORK;NLP COMPARISON;PROCESSES UML;PROLOG BASED;SEMANTIC REPRESENTATION;SENSORS INTERFACES;SOFTWARE ASSETS;UML ARTEFACTS;UNIFORM SEMANTIC;WATSON SERVICE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4,255,100,1,1,64,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;PATIENT SAFETY;PEDIATRIC;RARE DISEASES","1;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,1,0,0,6,6,3,1,2,0,0,"AZIENDA OSPEDALIERA UNIVERSITARIA UNIVERSITÀ DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI;IMPERIAL COLLEGE LONDON;UNIVERSITY OF ALBERTA;UNIVERSITY OF DUNDEE;UNIVERSITY OF EAST ANGLIA;UNIVERSITY OF NAPLES FEDERICO II","1;1;1;1;1;1","BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","STUDENTSHIP (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY","1;1","AUTOIMMUNE DISEASE;CLINICAL RESEARCH;DIGESTIVE DISEASES","1;1;1","INFECTION;ORAL AND GASTROINTESTINAL","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1",NA,NA,NA,NA,"A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2017,47,8.85106382978723,2.19148936170213,0.425531914893617,0.234042553191489,0.446808510638298,1.30379746835443,1,1,1,0.48936170212766,4,13,2,4,22,0.28,0.04,0.09,0.47,7.68,0.260588430945114,1.66666666666667,0.297872340425532,0.765957446808511,0.494,0.323,0.395,0.315,"ORONZIO MANCA;CIRO GALLO;FORTUNATO CIARDIELLO;BERNARDO BUONOMO;SERGIO NARDINI;SAVERIO CINIERI;CLAUDIA CARDONE;FEDERICA PERRONE;TERESA TROIANI;MARIA CARMELA PICCIRILLO;VIRGINIA GUTIÉRREZ‐DE JUAN;NICOLA NORMANNO;LAURA DELACRUZ‐VILLAR;FERDINANDO RICCARDI;MARIA GIUSEPPA SAROBBA;JOSÉ M. MATO;ANDREA LUCIANI;JOSÉ LUIS LAVÍN;FLORIANA MORGILLO;V. BELLI","8;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ORONZIO MANCA;ADRIANA ROSSI;FABIANA FORTE;ELENA LAUDANTE;MATILDE CIVITILLO;BERNARDO BUONOMO;RAIMONDO MANCA;SERGIO NARDINI;ROSANNA VERDE;ROBERTO IALENTI;LUCA PALERMO;ASSUNTA ANDREOZZI;ROSSANA PICCOLO;DAVIDE ERCOLE;ALESSANDRA DIANA;A.V. DE LUCA;FELIA ALLUM;SINIŠA ZARIĆ;LUCA CIRILLO;VINCENZO BIANCO","2.5;1;1;1;1;1;1;1;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5","ORONZIO MANCA;CIRO GALLO;FORTUNATO CIARDIELLO;CLAUDIA CARDONE;TERESA TROIANI;FLORIANA MORGILLO;V. BELLI;MICHELE ORDITURA;G. MARTINI;CARMINIA MARIA DELLA CORTE;PASQUALE VITALE;P.P. VITIELLO;ROSANNA VERDE;FEDERICA PAPACCIO;DONATELLA DELLE CAVE;D. CIARDIELLO;VINCENZO SFORZA;F. MORGILLO;VINCENZA CIARAMELLA;N. ZANALETTI","8;5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ORONZIO MANCA;ADRIANA ROSSI;FABIANA FORTE;ELENA LAUDANTE;MATILDE CIVITILLO;ROSANNA VERDE;LUCA PALERMO;ROSSANA PICCOLO;A.V. DE LUCA;GIUSEPPINA DI BLASIO;ANTONIO IRPINO;NICOLA PISACANE;ANNA COSTANZA BALDRY;RAFFAELA DE MARTINO;ROSSELLA FRANCHINO;FORTUNATO CIARDIELLO;MASSIMO FICCO;FEDERICA PAPACCIO;PASQUALE CONTESTABILE;ANGELICA PETRILLO","2.5;1;1;1;1;0.53;0.5;0.5;0.5;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.25;0.25;0.25;0.25","A. PEÑA;ANA M. ARANSAY;ARUN J. SANYAL;CRISTINA ALONSO;DAVID FERNÁNDEZ–RAMOS;DONATELLA DELLE CAVE;FÉLIX ELORTZA;IBON MARTÍNEZ‐ARRANZ;IGOR AURREKOETXEA;JORGE SIMÓN;JOSÉ LUIS LAVÍN;JOSÉ M. MATO;JUAN ANGUÍTA;JUAN MANUEL FALCÓN‐PÉREZ;JUAN RODRÍGUEZ‐CUESTA;LAURA DELACRUZ‐VILLAR;LIAT HAYARDENY;MARTA IRUARRIZAGA‐LEJARRETA;MARTA VARELA‐REY;MARÍA LUZ MARTÍNEZ‐CHANTAR","101;101;101;101;101;101;101;101;101;101;101;101;101;101;101;101;101;101;101;101","DONATELLA DELLE CAVE;ELENA LAUDANTE;ALESSIA PUCCIARELLI;CHIOSI EMILIO;FRANCESCA CAPRIO;MARIANNA SANTONASTASO;NATELLA ANTONELLA;NICOLA COLACURCI;MASSIMO FICCO;CLAUDIO NAPOLI;CIRO GALLO;GIUSEPPINA DI BLASIO;ANNA COSTANZA BALDRY;FRANCESCO PRECENZANO;ADRIANO STINCA;ALESSANDRO SANDUZZI;ANTONIO MOLINO;MARIA D’AMATO;MAURO MORMILE;SANDRO COSCONATI","101;63;53;53;53;53;53;53;37;34;15;12;11;9;8;6;6;6;6;6","ORONZIO MANCA;CIRO GALLO;DONATELLA DELLE CAVE;ADRIANO STINCA;ALESSANDRO SANDUZZI;ALESSIA PUCCIARELLI;ANNA COSTANZA BALDRY;ANTONIO MOLINO;CARLA LANGELLA;CHIOSI EMILIO;CLAUDIO NAPOLI;ELENA LAUDANTE;FLORIANA MORGILLO;FRANCESCA CAPRIO;FRANCESCO PRECENZANO;GIOVANNI COLONNA;GIUSEPPINA DI BLASIO;IDA RENZULLO;MARIA D’AMATO;MARIANNA SANTONASTASO","8;5;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;PHYSICS;BIOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;GEOGRAPHY;CHEMISTRY;ECONOMICS;GEOLOGY;POLITICAL SCIENCE;ART;ENVIRONMENTAL SCIENCE;HISTORY;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY","25;16;12;11;9;8;7;6;5;4;4;4;3;3;3;3;3;2","INTERNAL MEDICINE;ONCOLOGY;QUANTUM MECHANICS;COMPOSITE MATERIAL;MECHANICS;THERMODYNAMICS;ENVIRONMENTAL HEALTH;MECHANICAL ENGINEERING;ARCHAEOLOGY;BIOCHEMISTRY;CANCER RESEARCH;LAW;MATHEMATICAL ANALYSIS;OPERATING SYSTEM;PALEONTOLOGY;CELL BIOLOGY;ECOLOGY;ELECTRICAL ENGINEERING;GASTROENTEROLOGY;IMMUNOLOGY;METEOROLOGY;OPTICS;PURE MATHEMATICS","17;9;8;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CANCER;HEAT TRANSFER;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;COMPUTATIONAL FLUID DYNAMICS;DISEASE;POROSITY;PRESSURE DROP;TURBULENCE;CONTEXT (ARCHAEOLOGY);POISON CONTROL;POLITICS;POPULATION;PROPORTIONAL HAZARDS MODEL;ADIABATIC PROCESS;AIRFLOW;ALGEBRA OVER A FIELD;CHANNEL (BROADCASTING);CONVECTION;DIMENSION (GRAPH THEORY);EIGENVALUES AND EIGENVECTORS;FIBROSIS;GENERALIZATION;LATENT HEAT;LUNG CANCER;MATRIX (CHEMICAL ANALYSIS);PARTIAL DIFFERENTIAL EQUATION;POWER (PHYSICS);RADIATION;RECEPTOR;ROOF;THERMAL;THERMAL CONDUCTIVITY;THERMAL ENERGY","9;6;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;COLORECTAL CANCER;FLUENT;NATURAL CONVECTION;BREAST CANCER;CISPLATIN;FATTY LIVER;GEMCITABINE;HEAT FLUX;HEAT TRANSFER COEFFICIENT;INTERIM ANALYSIS;METAL FOAM;PERFORMANCE STATUS;PHASES OF CLINICAL RESEARCH;POROUS MEDIUM;REYNOLDS NUMBER;SUICIDE PREVENTION;SYMMETRIC MATRIX;TRIDIAGONAL MATRIX;A549 CELL;ACHILLES TENDON;ASTHMA ATTACK;AURA;BEAM SPLITTER;BEVACIZUMAB;CANCER CELL;CD8;CENSUS;CHEMOKINE;CHEMORADIOTHERAPY;CHEMOTHERAPY REGIMEN;CHIRAL COLUMN CHROMATOGRAPHY;CHIRAL SYMMETRY BREAKING;CORONARY ATHEROSCLEROSIS;CYTOTOXIC T CELL;EDGE COMPUTING;ENTHESIS;ENTHESOPATHY;EPIDERMAL GROWTH FACTOR RECEPTOR;FLORA (MICROBIOLOGY);FUZZY CLUSTERING;GAIT ANALYSIS;GAIT CYCLE;GENERATOR (CIRCUIT THEORY);GROWTH INHIBITION;HAZARD RATIO;HEAD AND NECK CANCER;HUMAN FACTORS AND ERGONOMICS;IMMUNOTHERAPY;INFLAMMATORY BOWEL DISEASE;INVESTMENT (MILITARY);LIGAND (BIOCHEMISTRY);LIVER FIBROSIS;MAJOR HISTOCOMPATIBILITY COMPLEX;MAPK/ERK PATHWAY;METHIONINE;MONOCLONAL ANTIBODY;NORMAL SUBGROUP;OOCYTE;PELVIC TILT;PERIPHERAL BLOOD MONONUCLEAR CELL;PI3K/AKT/MTOR PATHWAY;PROGRESSION-FREE SURVIVAL;PSORIATIC ARTHRITIS;RECEPTOR TYROSINE KINASE;REPRESENTATION (POLITICS);SELECTIVITY;T CELL;ULCERATIVE COLITIS;VASCULAR PLANT;WAVE ENERGY CONVERTER;WESTERN BLOT","4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CETUXIMAB;DOMESTIC VIOLENCE;NONALCOHOLIC FATTY LIVER DISEASE;NUSSELT NUMBER;OXALIPLATIN;PEMETREXED;RAYLEIGH NUMBER;SQUARE MATRIX;STATE-TRANSITION MATRIX;STEATOHEPATITIS;TAMOXIFEN;TRIDIAGONAL MATRIX ALGORITHM;ALIEN;CD28;CHEMOKINE RECEPTOR;CURE DATA CLUSTERING ALGORITHM;CYSTATHIONINE BETA SYNTHASE;ENTHESITIS;ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR (EPH) RECEPTOR;FOLLICULAR FLUID;HOMICIDE;IRINOTECAN;KRAS;MAXIMAL SUBGROUP;MEK INHIBITOR;MHC CLASS I;NAMBU–JONA-LASINIO MODEL;NON-SMALL CELL LUNG CANCER (NSCLC);TRASTUZUMAB","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";ASTHMA;CHEMOKINE CXCL11;HUMANS;RECEPTORS, CXCR3;CHEMOKINE CCL11;CHEMOKINE CXCL10;ENDOMETRIOSIS;FOLLICULAR FLUID;INSULIN;INTERLEUKIN-8;ISOENZYMES;L-LACTATE DEHYDROGENASE;LACTIC ACID;METABOLOMICS;PHOSPHOLIPIDS;POLLEN;VASCULAR ENDOTHELIAL GROWTH FACTOR A;ADULT;DISEASE OUTBREAKS","44;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BUILDING ENERGY EFFICIENCY AND THERMAL COMFORT OPTIMIZATION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;INTIMATE PARTNER VIOLENCE AND HEALTH CONSEQUENCES;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;RAILWAY ENGINEERING AND MATERIAL SCIENCE;SOLAR AIR HEATER HEAT TRANSFER ANALYSIS;3D GEOSPATIAL MODELLING TECHNIQUES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANCIENT NEAR EASTERN STUDIES AND CIVILIZATIONS;ARCHAEOLOGICAL STUDIES OF ANCIENT MEDITERRANEAN CIVILIZATIONS;CANCER IMMUNOTHERAPY;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLUSTERING OF TIME SERIES DATA AND ALGORITHMS;DESIGN THINKING AND ENGINEERING DESIGN PROCESSES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ENERGY STORAGE IN POWER SYSTEMS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;ANASTROZOLE;AROMATASE INHIBITOR;BAND MATRIX;DARCY NUMBER;EGFR;EXEMESTANE;FOLFOX;HEAT TRANSFER;IMPINGING JET;INTERIM ANALYSIS;INTIMATE PARTNER VIOLENCE;LETROZOLE;MATRIX (CHEMICAL ANALYSIS);MATRIX SPLITTING;METASTATIC COLORECTAL CANCER;NATURAL VENTILATION;NUMERICAL SOLUTION;PEMETREXED;PERFORMANCE STATUS","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER MCRC;RANDOMIZED PHASE;ADJUVANT ANASTROZOLE;BREAST CANCER;CANCER NSCLC;CHANNEL SYSTEM;CONFINED IMPINGING;ELDERLY PATIENTS;EXPERIMENTAL ANALYSIS;FATA-GIM TRIAL;FIRST-LINE CHEMOTHERAPY;GOIM TRIAL;HEAT THERMAL;HEAT TRANSFER;HORMONE-RESPONSIVE HR;HR BREAST;IMPINGING ROUND;JOINT ANALYSIS;K-DIMENSIONAL MATRICES;LATENT HEAT;LUNG CANCER;MCRC PATIENTS;MILES- STUDIES;MULTICENTRE RANDOMIZED;NATURAL CONVECTION;NUMERICAL SOLUTION;PARALLEL SQUARED;PATIENTS PTS","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VENTILATED ROOF;CELL LINES;HR CI;MEDIAN AGE;RESPONSE RATE;DI DIANO;MCRC PTS;MEDIAN FOLLOW-UP;MEDIAN OS;NATIONAL PARK;PTS TREATED;VALLO DI;DIANO NATIONAL;DISEASE PROGRESSION;HEAT TRANSFER;HFV SET;MONTHS HR;NRAS BRAF;OPTIMAL THERMAL;PIKCA WT;REACH OPTIMAL;SOLAR RADIATION;TEMPERATURE VALUES;TOP WALL;VENTILATED CHANNEL;VENTILATED LAYER;WINTER CONDITIONS;WINTER REGIMES;ADVANCED NSCLC;BRAF PIKCA","8;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3",2,0.04,318.25,46,1,0,0,53,2,0,0,46,1,0,5,0,0,1,0,2,2,0,0,61.75,61.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3.67,322.33,4.29,2,0.67,69.67,0,0,2,0,0,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"United States;Germany;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","3;3;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;ALS;AUTOIMMUNE DISEASE;BRAIN DISORDERS;LUPUS;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES","3;2;2;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","1;1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;2;1",NA,NA,NA,NA,1,627583,69731.44,5,9,5,1,11,13946.2888888889,3.37007216575337,"AZIENDA OSPEDALIERA UNIVERSITARIA UNIVERSITÀ DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI;DIAMOND LIGHT SOURCE;HANNOVER MEDICAL SCHOOL;QUADRAM INSTITUTE;UNIVERSITY OF CALIFORNIA, BERKELEY;UNIVERSITY OF EAST ANGLIA;UNIVERSITY OF OXFORD;UNIVERSITY OF YORK;UTRECHT UNIVERSITY","1;1;1;1;1;1;1;1;1","BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","RESEARCH GRANT (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY","1;1;1","BIODEFENSE;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;NUTRITION;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1","INFECTION;ORAL AND GASTROINTESTINAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","1;1",NA,NA,NA,NA,"A05 BIOLOGICAL SCIENCES","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2018,51,7.25490196078431,1.7843137254902,0.549019607843137,0.313725490196078,0.725490196078431,1.21333333333333,1.12,1.23076923076923,1.08823529411765,0.450980392156863,8,11,4,4,21,0.22,0.08,0.08,0.41,14.75,0.483315036827784,2.13513513513514,0.392156862745098,0.745098039215686,0.56,0.254,0.429,0.314,"ORONZIO MANCA;FORTUNATO CIARDIELLO;YOGESH JALURIA;BERNARDO BUONOMO;FLORIANA MORGILLO;JOSEP TABERNERO;DAVIDE ERCOLE;CARMINIA MARIA DELLA CORTE;FRANCESCO SAVERIO MENNINI;ASSUNTA ANDREOZZI;TERESA TROIANI;ELENA LANATI;FRANCESCA FANELLI;GIORGIA BEVILACQUA;PAOLA LA MALFA;MADDALENA CASALE;SILVERIO PERROTTA;ARIANNA IORIO;S GENTILE;FEDERICA PAPACCIO","8;6;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ORONZIO MANCA;GIORGIA BEVILACQUA;YOGESH JALURIA;DOMENICA BORRIELLO;JAVIER VERDEJO VAQUERO;VINCENZO CIRILLO;MARIA DOLORES MORELLI;VITO NAPOLITANO;NICOLA PALLADINO;BERNARDO BUONOMO;DAVIDE ERCOLE;FORTUNATO CIARDIELLO;ASSUNTA ANDREOZZI;CONCETTA CUSANO;CLAUDIA CENNAMO;А. С. ДЕНИКИН;Б. А. УРАЗБЕКОВ;SERGIO NARDINI;FLORIANA MORGILLO;CARMINIA MARIA DELLA CORTE","2.9;2;2;1;1;1;1;1;1;0.9;0.7;0.56;0.5;0.5;0.5;0.5;0.5;0.4;0.37;0.37","ORONZIO MANCA;FORTUNATO CIARDIELLO;FLORIANA MORGILLO;CARMINIA MARIA DELLA CORTE;TERESA TROIANI;GIORGIA BEVILACQUA;S GENTILE;CLAUDIO NAPOLI;FRONGILLO ELISABETTA MARIA;CARLO GAROFALO;DIEGO VICINANZA;SERENA FASANO;FERDINANDO DE VITA;ANTONIO SORRIENTO;CIRO GALLO;GIOVANNA CUOMO;LUCIA MICHELA DANIELE;BARBARA IODICE;ROSSELLA VASTARELLA;ANGELA BELSITO","8;6;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ORONZIO MANCA;GIORGIA BEVILACQUA;DOMENICA BORRIELLO;JAVIER VERDEJO VAQUERO;VINCENZO CIRILLO;MARIA DOLORES MORELLI;VITO NAPOLITANO;NICOLA PALLADINO;FORTUNATO CIARDIELLO;CONCETTA CUSANO;CLAUDIA CENNAMO;Б. А. УРАЗБЕКОВ;FLORIANA MORGILLO;CARMINIA MARIA DELLA CORTE;CHIARA BRACONI;S GENTILE;MATTIA BRESCIA;MARTA PANELLA;CLELIA MAZZONI;LUCIA MICHELA DANIELE","2.9;2;1;1;1;1;1;1;0.56;0.5;0.5;0.5;0.37;0.37;0.33;0.33;0.33;0.33;0.33;0.25","FORTUNATO CIARDIELLO;JOSEP TABERNERO;ALEXANDRU ENIU;ANDRÉ ILBAWI;BRANISLAV BYSTRICKÝ;CAMILLA QVORTRUP;CARMEN CRISCITIELLO;CHRISTOPH ZIELINSKI;ECE ESIN;FÁTIMA CARDOSO;GABE S. SONKE;GERALD W. PRAGER;GRACEMARIE BRICALLI;GUILLEMARGILÉS MARTÍNEZ;JEAN-YVES DOUILLARD;JEAN‐SÉBASTIEN FRENEL;KEITH MCGREGOR;MALVIKA VYAS;MICHALIS V. KARAMOUZIS;MICHIEL STRIJBOS","354;276;228;228;228;228;228;228;228;228;228;228;228;228;228;228;228;228;228;228","FORTUNATO CIARDIELLO;TERESA TROIANI;ANTONIO MELES;FRANCESCO GANGI;LUCIA MICHELA DANIELE;ANNA MARIA BARBARULO;CLAUDIO NAPOLI;ADRIANO STINCA;NICOLA OLIVIERI;R. BUOMPANE;GIUSEPPE LIMONGELLI;GIUSEPPE PACILEO;ROSSELLA VASTARELLA;ANGELA BELSITO;CARMELA FIORITO;DARIO COSTA;DOMENICO COZZOLINO;ANNA DIANA;CARMINIA MARIA DELLA CORTE;E. FRANZESE","354;228;210;210;210;48;25;24;24;23;21;21;21;15;15;15;14;11;11;11","FORTUNATO CIARDIELLO;CLAUDIO NAPOLI;GIORGIA BEVILACQUA;TERESA TROIANI;A. RAIMONDO;ADRIANO STINCA;ANGELA BELSITO;ANGELA RUSSO;ANNA DIANA;ANNA MARIA BARBARULO;ANTONELLA ESPOSITO;ANTONELLA RICCARDI;ANTONIO MELES;ANTONIO SORRIENTO;BARBARA IODICE;CARLO GAROFALO;CARMELA FIORITO;CARMELA IANNONE;CARMINIA MARIA DELLA CORTE;CHIARA BRACONI","7;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;COMPUTER SCIENCE;PHYSICS;BIOLOGY;ENGINEERING;MATERIALS SCIENCE;PSYCHOLOGY;ART;BUSINESS;CHEMISTRY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY;HISTORY;PHILOSOPHY;SOCIOLOGY","25;14;14;13;9;7;6;5;5;5;5;5;5;4;2;2;2;2;2","INTERNAL MEDICINE;BIOCHEMISTRY;ONCOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;MECHANICS;QUANTUM MECHANICS;THERMODYNAMICS;COMPOSITE MATERIAL;ENVIRONMENTAL HEALTH;IMMUNOLOGY;LAW;ARCHAEOLOGY;COMPUTER SECURITY;ECOLOGY;ENDOCRINOLOGY;FINANCE;HUMANITIES;OPERATING SYSTEM;PALEONTOLOGY;PSYCHIATRY;RADIOLOGY","19;6;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CANCER;DISEASE;THERMAL;HEAT TRANSFER;POPULATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;GENE;HEART FAILURE;ADVERSE EFFECT;ANTIGEN;BACTERIA;CLINICAL TRIAL;DIABETES MELLITUS;ENERGY (SIGNAL PROCESSING);IMMUNE SYSTEM;IN VITRO;INTERNATIONAL LAW;LATENT HEAT;LEGISLATION;MAGNETIC RESONANCE IMAGING;MARITIME SECURITY;POLITICS;PRIVATE SECURITY;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;SIGNAL TRANSDUCTION;THALASSEMIA;TRANSPLANTATION;TREATY","7;7;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MAPK/ERK PATHWAY;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;T CELL;A549 CELL;AGONIST;AMPLIFIER;ANOSOGNOSIA;ARMOUR;ARRHENIUS EQUATION;AUTOIMMUNE DISEASE;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BACTEREMIA;BEVACIZUMAB;BREAST CANCER;CANCER PREVENTION;CARDIAC FUNCTION CURVE;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIOMYOPATHY;CD8;CHEMOTHERAPY REGIMEN;CHIMNEY (LOCOMOTIVE);CITIZENSHIP;COGNITIVE IMPAIRMENT;COMPLETE REMISSION;CONSTRUCTIVE;CYTOTOXIC T CELL;DEFERASIROX;DEMENTIA;DIABETIC FOOT;DILATED CARDIOMYOPATHY;DOCETAXEL;EJECTION FRACTION;ELECTRICITY GENERATION;EPIDERMAL GROWTH FACTOR RECEPTOR;EX VIVO;FLAG (LINEAR ALGEBRA);FLORA (MICROBIOLOGY);FLUENT;GENOTYPE;GLOBAL HEALTH;GLYCOPEPTIDE;HEALTH EQUITY;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;HYPERURICEMIA;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;LOG-RANK TEST;MAJOR HISTOCOMPATIBILITY COMPLEX;MARINE ENERGY;METABOLIC BONE DISEASE;METAL FOAM;MICRORNA;NATURAL CONVECTION;NEURAL CORRELATES OF CONSCIOUSNESS;NOMENCLATURE;PAGET'S DISEASE OF BONE;PASSIVE SOLAR BUILDING DESIGN;PERMEABILITY (ELECTROMAGNETISM);PHENOTYPE;PI3K/AKT/MTOR PATHWAY;POLYCYSTIC KIDNEY DISEASE;POROUS MEDIUM;PRIMARY SCLEROSING CHOLANGITIS;PROTEIN KINASE B;PULSE (MUSIC);PULSE RATE;REPRESENTATION (POLITICS);SOCIAL TRUST;SOLAR CHIMNEY;STAKEHOLDER THEORY;STAPHYLOCOCCUS AUREUS;SYSTEMIC LUPUS ERYTHEMATOSUS;TARGETED THERAPY;TOLERABILITY;TOLVAPTAN;TYPE 2 DIABETES;VASCULAR PLANT;WAITING LIST;WAVE ENERGY CONVERTER;WHITE MATTER","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KRAS;MEK INHIBITOR;ALIEN;BILIARY CIRRHOSIS;CETUXIMAB;CLINICAL DEMENTIA RATING;COMPLEMENTATION;CORONAVIRUS DISEASE 2019 (COVID-19);CTL*;ERLOTINIB;FEBUXOSTAT;GEFITINIB;GENE POLYMORPHISM;HISTOCOMPATIBILITY;HISTOCOMPATIBILITY TESTING;IL-2 RECEPTOR;INSULIN ASPART;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MHC CLASS I;NIVOLUMAB;NON-SMALL CELL LUNG CANCER (NSCLC);OBETICHOLIC ACID;OXALIPLATIN;PEMBROLIZUMAB;POLYMORPHISM (COMPUTER SCIENCE);PREAMPLIFIER;RAYLEIGH NUMBER;REGORAFENIB;VOXEL-BASED MORPHOMETRY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;BETA-THALASSEMIA;ARRHYTHMIAS, CARDIAC;FEMALE;HYPERURICEMIA;IRON OVERLOAD;BLOOD TRANSFUSION;MALE;ADULT;ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS;BREAST NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;HLA-G ANTIGENS;LUNG NEOPLASMS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;PRACTICE GUIDELINES AS TOPIC;STAPHYLOCOCCAL INFECTIONS;TOLVAPTAN","42;9;7;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","MICROCHANNEL HEAT TRANSFER AND COOLING TECHNOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;ECONOMY OF KNOWLEDGE AND INNOVATION;MARITIME SECURITY AND PIRACY IN ASIA-PACIFIC REGION;3D GEOSPATIAL MODELLING TECHNIQUES;ART HISTORY AND CONSERVATION IN SPAIN;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CORPORATE SOCIAL RESPONSIBILITY AND FINANCIAL PERFORMANCE;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DISEASES RELATED TO BLOOD GROUP VARIANTS;EDUCATION AND PEDAGOGY RESEARCH;EFFECTS OF NOISE POLLUTION ON HEALTH AND WELL-BEING;ENERGY STORAGE IN POWER SYSTEMS;EXPANDING ACCESS TO RADIOTHERAPY GLOBALLY;FLAME RETARDANT POLYMER MATERIALS","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CONVECTIVE HEAT TRANSFER;HEAT EXCHANGERS;HEAT TRANSFER;NUMERICAL SIMULATION;EXPERIMENTAL STUDY;METASTATIC COLORECTAL CANCER;ATEZOLIZUMAB;CLINICAL ENDPOINT;COST-EFFECTIVENESS ANALYSIS;MARITIME SECURITY;PIRACY;PRIVATE SECURITY;THERMAL MANAGEMENT;;ACOUSTIC EMISSION;ALLOPURINOL;ANOSOGNOSIA;ANTIGEN PRESENTATION;ARMOUR;ARTERIOSCLEROSIS","5;5;5;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","COMPUTATIONAL HEAT;HEAT TRANSFER;TRANSFER CHT-;COLORECTAL CANCER;PREFACE ADVANCES;AD AZIONE;ANALISI DI;ANALOGHI AD;APPARENT HYBRID;ARMED ON-BOARD;AZIONE RAPIDA;BUDGET DI;DI DIFFERENTI;DI IMPATTO;DIFFERENTI ANALOGHI;FLUID DYNAMIC;HYBRID MODEL;III STUDY;IMPATTO SUL;ITALIAN SHIPS;KIDNEY DISEASE;METASTATIC COLORECTAL;ON-BOARD PROTECTION;PHASE III;PRIVATE CONTRACTORS;RAPIDA DELLINSULINA;REGULATED RISE;SUL BUDGET;THERMAL ENERGY;ABNORMAL BASELINE","4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","WIDE RANGE;ATEZOLIZUMAB MONOTHERAPY;CONTRIBUTED PAPERS;HEAT TRANSFER;IG MARKET;NHS EXPENDITURE;PROLONGED REMISSION;HR CI;MARKET SHARE;SPECIAL ISSUE;IRON OVERLOAD;ADDITIONAL DETAILS;APPLIED INTERESTTHE;BATH UK;BUDGET IMPACT;CARDIAC FUNCTION;CESME TURKEY;CHT PRACTITIONERS;COMPLETED PAPERS;COMPUTATIONAL HEAT;COMPUTATIONAL TECHNIQUES;CURRENT SCENARIO;CV EVENT;EXPANDEDTHE SUBMITTED;EXTENDED ABSTRACTSTHESE;FUTURE NEEDSDURING;II NAPOLI;INCLUDE ADDITIONAL;INCLUDING CESME;INTERESTTHE MAIN","10;9;8;8;8;8;8;7;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",9,0.18,9.5,3,0,3,1,1.5,1,0,2,4,1,0,8.5,0,0,2,4,10,4.5,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3.33,322.67,4,3,1,67.33,0,0,1,0,2,0,0,0,0,3,0,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,0,0,0,0,"Japan;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","3;2;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MENTAL HEALTH;MUSCULAR DYSTROPHY;NEUROSCIENCES;PEDIATRIC;RARE DISEASES;SCHIZOPHRENIA","3;3;2;1;1;1;1;1;1;1;1","MUSCULOSKELETAL","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","3;1",NA,NA,NA,NA,1,5998516,666501.78,6,9,4,1,4,125029.918518519,0.407902369323277,"AZIENDA OSPEDALIERA UNIVERSITARIA UNIVERSITÀ DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI;GENETHON (FRANCE);GENOSAFE;HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ;REITHERA (ITALY);ROTTERDAM EYE HOSPITAL;TELETHON FOUNDATION;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF MILANO-BICOCCA","1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","1;1","BIOTECHNOLOGY;EYE DISEASE AND DISORDERS OF VISION;GENE THERAPY;GENETICS;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1;1","EYE","1","5.2 CELLULAR AND GENE THERAPIES","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2019,55,8.4,1.92727272727273,0.527272727272727,0.236363636363636,0.545454545454545,1.12903225806452,1.07692307692308,1,1.07407407407407,0.509090909090909,14,12,7,5,20,0.22,0.13,0.09,0.36,5.98,0.245994403753077,4.29268292682927,0.363636363636364,0.690909090909091,0.592,0.216,0.241,0.21,"FORTUNATO CIARDIELLO;PIETRO PAOLO VITIELLO;DAVIDE CIARDIELLO;VINCENZO DE FALCO;CLAUDIA CARDONE;L. POLIERO;PASQUALE VITALE;TERESA TROIANI;N. ZANALETTI;ERIKA MARTINELLI;C. BORRELLI;EMILIO FRANCESCO GIUNTA;FRANCESCO PASTORE;FRANCESCA CATALANO;FRANCESCO MESSINA;VINCENZA CAPUTO;LAURA SAINATI;MONICA PINTO;SERENA CUBISINO;AGOSTINO STEFFAN","5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","FRANCESCO PASTORE;MANUELA PISCITELLI;PAOLO GRITTI;ANGELO DI FALCO;FORTUNATO GAMBARDELLA;NICOLA DE LUCA;SIMONETTA CONTI;ORNELLA ZERLENGA;GIANVITO BRINDISI;DIEGO MATRICANO;ANNA GRIMALDI;ANNA ESPOSITO;VALENTINA PERRICONE;DOMINIQUE ORBAN;CARLA LANGELLA;AMELIA TREMATERRA;GINO IANNACE;ALFREDO BUCCARO;DANIELA DI SERAFINO;CIRO ROBOTTI","2.33;2;1;1;1;1;1;1;1;1;1;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5","FORTUNATO CIARDIELLO;DAVIDE CIARDIELLO;TERESA TROIANI;ERIKA MARTINELLI;FRANCESCO PASTORE;ANNA ESPOSITO;PAOLO GOLINO;MANUELA PISCITELLI;AMELIA TREMATERRA;GINO IANNACE;MADDALENA CASALE;SILVERIO PERROTTA;GUGLIELMO THOMAS;CLAUDIO NAPOLI;GIUSEPPE CIABURRO;GIOVANNI FRANCESCO NICOLETTI;ALFONSO DESIDERIO;PAOLO GRITTI;OSPEDALE A. CARDARELLI;GEMMA SALERNO","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","FRANCESCO PASTORE;MANUELA PISCITELLI;PAOLO GRITTI;ANGELO DI FALCO;FORTUNATO GAMBARDELLA;NICOLA DE LUCA;SIMONETTA CONTI;ORNELLA ZERLENGA;GIANVITO BRINDISI;DIEGO MATRICANO;ANNA GRIMALDI;ANNA ESPOSITO;CARLA LANGELLA;AMELIA TREMATERRA;GINO IANNACE;DANIELA DI SERAFINO;CIRO ROBOTTI;LUCAS FABIÁN OLIVERO;GIUSEPPE CIABURRO;GIOVANNA CAPOLONGO","2.33;2;1;1;1;1;1;1;1;1;1;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.33","ANNA COSTANZA BALDRY;ANNA SORRENTINO;CATHERINE BLAYA;DAVID P. FARRINGTON;ALESSANDRA ROSSI;ALESSANDRA RUFFA;ALESSANDRO ARMUZZI;AMBROGIO ORLANDO;ANNA TESTA;ANNA VIOLA;BENEDETTO NERI;C. PETRUZZIELLO;CLAUDIO PAPI;ELENA DE CRISTOFARO;EMMA CALABRESE;FABIANA CASTIGLIONE;FILIPPO MOCCIARO;FRANCESCA ROGAI;GABRIELE RIEGLER;GIANMICHELE MEUCCI","63;63;63;63;59;59;59;59;59;59;59;59;59;59;59;59;59;59;59;59","ANNA SORRENTINO;GABRIELE RIEGLER;MARTA PATTURELLI;MARIA ROSARIA MONSURRÒ;NICOLA CROCETTO;ROSA MAISTO;SERENA FASANO;GIOVANNA BATTIPAGLIA;GINO IANNACE;GIUSEPPE FAELLA;MARIANNA AURILIO;MARIATERESA GUADAGNUOLO;GIOVANNI CONZO;NICOLA COPPOLA;DIEGO MATRICANO;CARLA LANGELLA;LUCAS FABIÁN OLIVERO;FIORINA CASALE;GIOVANNA CAPOLONGO;LINDA SOMMESE","63;59;59;53;20;19;16;15;10;10;10;10;9;9;8;7;7;6;6;6","FRANCESCO PASTORE;DAVIDE CIARDIELLO;TERESA TROIANI;ERIKA MARTINELLI;GINO IANNACE;GUGLIELMO THOMAS;MADDALENA CASALE;MANUELA PISCITELLI;AMELIA TREMATERRA;ANNA SORRENTINO;CARLA LANGELLA;CLAUDIO NAPOLI;DIEGO MATRICANO;FABIO ORESTE RINALDI;FIORINA CASALE;FRANCESCO CICCIA;GABRIELE RIEGLER;GENNARO CORDASCO;GIOVANNA BATTIPAGLIA;GIOVANNA CAPOLONGO","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;POLITICAL SCIENCE;BIOLOGY;COMPUTER SCIENCE;PHILOSOPHY;PHYSICS;ART;BUSINESS;ECONOMICS;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;GEOGRAPHY;HISTORY;CHEMISTRY;ENVIRONMENTAL SCIENCE;GEOLOGY;MATERIALS SCIENCE","28;11;10;10;8;8;7;7;7;7;7;7;6;5;5;2;2;2;1","INTERNAL MEDICINE;LAW;PATHOLOGY;ARTIFICIAL INTELLIGENCE;EPISTEMOLOGY;GEOMETRY;ONCOLOGY;QUANTUM MECHANICS;ARCHAEOLOGY;ENDOCRINOLOGY;HUMANITIES;RADIOLOGY;SURGERY;VISUAL ARTS;BIOCHEMISTRY;ECONOMIC GROWTH;ENVIRONMENTAL HEALTH;GENETICS;MARKETING;METEOROLOGY;NEUROSCIENCE;OPTICS;PHARMACOLOGY;PSYCHOTHERAPIST","22;11;7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CANCER;POLITICS;CHEMOTHERAPY;ADVERSE EFFECT;DISEASE;CONTEXT (ARCHAEOLOGY);GENE;PERSPECTIVE (GRAPHICAL);POINT (GEOMETRY);POPULATION;ANGIOGENESIS;APOPTOSIS;ARTIFICIALITY;CENTRAL NERVOUS SYSTEM;CEREBROSPINAL FLUID;CLINICAL TRIAL;CONSTRAINT (COMPUTER-AIDED DESIGN);DIABETES MELLITUS;EPIDEMIOLOGY;IMMUNOHISTOCHEMISTRY;INFLAMMATION;MEDITERRANEAN DIET;NATURALNESS;PAINTING;RETROSPECTIVE COHORT STUDY;THE IMAGINARY","9;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;REPRESENTATION (POLITICS);AUTOPHAGY;BREAST CANCER;PROGRESSION-FREE SURVIVAL;TOLERABILITY;ACCRUAL;ACOUSTIC ATTENUATION;ACOUSTIC METAMATERIALS;AMYOTROPHIC LATERAL SCLEROSIS;APHERESIS;ARCHITECTURAL ACOUSTICS;ARTICULATION (SOCIOLOGY);AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BEVACIZUMAB;CALL FOR BIDS;CARDIOGENIC SHOCK;CD8;CERVICAL CANCER;CERVIX;CISPLATIN;CLINICAL ENDPOINT;CLOSED-END FUND;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CROHN'S DISEASE;DENDROCLIMATOLOGY;DILATED CARDIOMYOPATHY;DOWNREGULATION AND UPREGULATION;EJECTION FRACTION;ENERGY MANAGEMENT;EPIDERMAL GROWTH FACTOR RECEPTOR;FLUOROURACIL;FUND OF FUNDS;GEMCITABINE;GENE EXPRESSION;GENOTYPE;GLYCEMIC;GROWTH FACTOR RECEPTOR;HIGH-FRUCTOSE CORN SYRUP;HOSPITALITY;IMMUNOTHERAPY;INFLAMMATORY BOWEL DISEASE;INSTITUTIONAL INVESTOR;INVESTMENT (MILITARY);JOB MARKET;KRYLOV SUBSPACE;LEGITIMACY;LIFE EXPECTANCY;LIQUID BIOPSY;METABOLIC SYNDROME;MICRORNA;MIDBRAIN;MITRACLIP;MUCOSITIS;NEOVASCULARIZATION;NEUTROPENIA;NOISE BARRIER;NOISE CONTROL;OBSTRUCTIVE HYDROCEPHALUS;PAYLOAD (COMPUTING);PHASE-CONTRAST IMAGING;PHASES OF CLINICAL RESEARCH;PLACEBO;POLYCYSTIC KIDNEY DISEASE;PROGENITOR CELL;PROINFLAMMATORY CYTOKINE;PSEUDOANEURYSM;RELATIONAL CAPITAL;RETICULAR FORMATION;RETINAL PIGMENT EPITHELIUM;RHINOPLASTY;ROOM ACOUSTICS;SCLERODERMA (FUNGUS);SEMINOMA;SICKLE CELL ANEMIA;SUSTAINABLE DESIGN;TRANSPIRATION;ULCERATIVE COLITIS;UNREINFORCED MASONRY BUILDING;ZERO-ENERGY BUILDING","6;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CETUXIMAB;IRINOTECAN;ACUTE CHEST SYNDROME;BECN1;CAPECITABINE;CD3;GLYCEMIC INDEX;KRAS;LASER CAPTURE MICRODISSECTION;MICROVESICLES;OXALIPLATIN;PASSIVE MANAGEMENT;PEMBROLIZUMAB;PEMETREXED;PHARMACOGENETICS;REGORAFENIB;RETICULAR ACTIVATING SYSTEM;RILUZOLE;SOD1;THYMIDYLATE SYNTHASE;VAPOUR PRESSURE DEFICIT","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MALE;DEOXYCYTIDINE;FLUOROURACIL;HEART FAILURE;HEART ANEURYSM;MIDDLE AGED;CAPECITABINE;COLONIC NEOPLASMS;FEMALE;MITRAL VALVE INSUFFICIENCY;OLEANOLIC ACID;POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;YOUNG ADULT;ADENOCARCINOMA;BLOOD COMPONENT TRANSFUSION;BLOOD TRANSFUSION;CARDIAC SURGICAL PROCEDURES","45;9;8;8;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ARCHAEOASTRONOMY AND CULTURAL LANDSCAPES;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;3D GEOSPATIAL MODELLING TECHNIQUES;ACOUSTIC METAMATERIALS AND PHONONIC CRYSTALS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ARCHAEOLOGICAL STUDIES OF ANCIENT MEDITERRANEAN CIVILIZATIONS;ARCHITECTURAL GEOMETRY AND ARTISTIC REPRESENTATION;BANKING AND FINANCE IN ECONOMIC SYSTEMS;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;BULLYING BEHAVIORS AND PSYCHOLOGICAL IMPACT;CANCER IMMUNOTHERAPY;CAUSES AND IMPACTS OF CLIMATE CHANGE OVER MILLENNIA;CEREMONIAL AND AUTHORITY IN MEDIEVAL ROME;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CIVIL ENGINEERING AND CONSTRUCTION;DESIGN AND MANAGEMENT OF WATER DISTRIBUTION NETWORKS;DESIGN THINKING AND ENGINEERING DESIGN PROCESSES;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METASTATIC COLORECTAL CANCER;REPRESENTATION (POLITICS);ANCIENT ARCHITECTURE;ARTIFICIALITY;DIET QUALITY;HEALTHY EATING INDEX;LABOR MARKETS;MEDITERRANEAN DIET;PROGRESSION-FREE SURVIVAL;SICKLE-CELL DISEASE;THE IMAGINARY;TOLERABILITY;3D MAPPING;3D MODELING;3D RECONSTRUCTION;ACOUSTIC ATTENUATION;ACOUSTIC METAMATERIALS;ACOUSTIC RHINOMETRY;ACUTE CHEST SYNDROME;AERIAL SURVEY","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","COLORECTAL CANCER;METASTATIC COLORECTAL;BREAST CANCER;CELL DISEASE;DEDICA STUDY;EMPLOYMENT SERVICES;MEDITERRANEAN DIET;PAINTED GARDENS;RETROSPECTIVE STUDY;ROMAN PAINTED;SICKLE CELL;STRUCTURAL ANALYSIS;ACOUSTIC BARRIER;ACOUSTIC CORRECTION;ACTIVATING SYSTEM;ACTIVITY INDEX;ACUTE CHEST;ACUTE EVENTS;ADVANCED SQUAMOUS;ADVERSE ACUTE;ALAR BASE;ALS CO-ALS;ALS PROTOCOL;AMERICAN COUNTRIES;ANALYSIS PURPOSE;ANALÓGICA DESCUBRIENDO;ANTI-EPIDERMAL GROWTH;ARPE- CELLS;ASCENDING RETICULAR;ASYMPTOMATIC AZYGOS","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MONTHS CI;LIQUID BIOPSY;RISK FACTORS;COLORECTAL CANCER;AUTOPHAGY PATHWAY;CELGENE PFIZER;IBD PATIENTS;OSA PATIENTS;RASBRAF WT;RECURRENT ACS;SALIVARY GLANDS;TRAINING PROGRAM;TUMOUR TISSUE;ACS EPISODES;ADVERSE EVENTS;AGE RANGE;AIEOP GUIDELINES;ARPE- CELLS;AUTOPHAGY GENES;BOWEL DISEASE;CENTER MALES;CLINICAL CHARACTERISTICS;CLINICAL PRACTICE;CULTURAL HERITAGE;DIASTOLIC FUNCTION;GENOTYPES HBSS;HBSC HBSΒ;HBSS HBSC;INCIDENT CANCER;INFLAMMATORY BOWEL","8;7;7;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",6,0.11,7.71,3,3,0,0,1,0,0,0,3,0,0,2.75,0,0,1,1.75,3,2,0,0,31,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4.75,234.75,4.65,3,0.75,86,0,0,2,0,2,0,0,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;3;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;CANCER;PEDIATRIC;RARE DISEASES;AUTOIMMUNE DISEASE;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;PATIENT SAFETY;PREVENTION","4;4;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","4;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2020,63,6.92063492063492,1.42857142857143,0.53968253968254,0.301587301587302,0.571428571428571,1.28169014084507,1.25,1.11764705882353,1.23333333333333,0.507936507936508,13,11,6,2,23,0.17,0.1,0.03,0.37,8.56,0.339525486156896,4.27272727272727,0.26984126984127,0.666666666666667,0.508,0.266,0.337,0.256,"FRANCESCO PASTORE;AMELIA TREMATERRA;GINO IANNACE;GIUSEPPE CIABURRO;LUCIANA SCUOTTO;ANNALISA CAPUANO;ÖMER TUĞSAL DORUK;SIMONE FERRERO;LUCIA MICHELA DANIELE;ELENA SEMERIKOVA;LUIGI ATRIPALDI;ANNA ESPOSITO;GERARDO BOTTI;PAOLO A. ASCIERTO;NICOLA VARRONE;SEBASTIANO COSTA;FRANCESCO GANGI;ADRIANO D’ALOIA;CLIFFORD STEVENSON;PAOLO CHIODINI","7;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FRANCESCO PASTORE;ADRIANO D’ALOIA;LUCIANA SCUOTTO;AMELIA TREMATERRA;ÖMER TUĞSAL DORUK;LUCA EMANUEL PINTO;SALVATORE DI COSTANZO;ELENA SEMERIKOVA;OSVALDO SACCHI;RICCARDO SERRAGLIO;NICOLA DE LUCA;GINO IANNACE;MARIA GABRIELLA PEZONE;ASTRID PELLICANO;MATILDE CIVITILLO;DANIELA PISCITELLI;OLIVIER BUTZBACH;ILARIA CRISTOFARO;GIUSEPPE CIABURRO;SILVIA RAUCCI","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FRANCESCO PASTORE;AMELIA TREMATERRA;GINO IANNACE;GIUSEPPE CIABURRO;LUCIANA SCUOTTO;LUCIA MICHELA DANIELE;ANNA ESPOSITO;NICOLA VARRONE;SEBASTIANO COSTA;FRANCESCO GANGI;ADRIANO D’ALOIA;PAOLO CHIODINI;GENNARO CORDASCO;LELIO CAMPANILE;GIOVANNI COLOMBO;VINCENZO FARDELLA;SERENA FASANO;MAURO IACONO;MARIO LUISO;LUCA EMANUEL PINTO","7;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","FRANCESCO PASTORE;ADRIANO D’ALOIA;LUCIANA SCUOTTO;AMELIA TREMATERRA;LUCA EMANUEL PINTO;SALVATORE DI COSTANZO;OSVALDO SACCHI;RICCARDO SERRAGLIO;NICOLA DE LUCA;GINO IANNACE;MARIA GABRIELLA PEZONE;ASTRID PELLICANO;MATILDE CIVITILLO;DANIELA PISCITELLI;OLIVIER BUTZBACH;ILARIA CRISTOFARO;GIUSEPPE CIABURRO;SILVIA RAUCCI;LUCIA MICHELA DANIELE;NICOLA VARRONE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0.53;0.53","FRANCESCO GANGI;LUCIA MICHELA DANIELE;NICOLA VARRONE;CARLO SALVARANI;ALESSANDRA BORTOLUZZI;ALESSANDRO MATHIEU;AMATO DE PAULIS;ANDREA DI MATTEO;ANDREA DORIA;ANGELA CERIBELLI;ANGELO VACCA;ANTONELLA LARIA;ANǴELA TINCANI;CARLO SELMI;CHIARA TANI;ELENA BARTOLONI;ELISA GREMESE;ENRICA BOZZOLO;ENRICO BRUNETTA;FABRIZIO CONTI","177;177;177;100;89;89;89;89;89;89;89;89;89;89;89;89;89;89;89;89","FRANCESCO GANGI;LUCIA MICHELA DANIELE;NICOLA VARRONE;FRANCESCO CICCIA;SERENA FASANO;SEBASTIANO COSTA;FERDINANDO ZULLO;CHIARA RESNATI;GIUSEPPE COLELLA;ANNA ESPOSITO;GENNARO CORDASCO;GENNARO RAIMO;MARIA COSCIA;MASSIMILIANO CONSON;PAOLO CHIODINI;MARIO LUISO;AMELIA TREMATERRA;CIRO NATALE;GIOVANNI SALZILLO;GIUSEPPE CIABURRO","177;177;177;89;89;41;38;24;23;20;20;18;18;18;17;14;12;12;12;12","FRANCESCO PASTORE;AMELIA TREMATERRA;GIUSEPPE CIABURRO;ANNA ESPOSITO;FRANCESCO GANGI;GENNARO CORDASCO;GINO IANNACE;LUCIA MICHELA DANIELE;NICOLA VARRONE;PAOLO CHIODINI;SEBASTIANO COSTA;ADRIANA GALDERISI;ADRIANA ROSSI;ADRIANO COSTIGLIOLA;ADRIANO STINCA;AMALIA DE LEO;CHIARA RESNATI;CIRO GALLO;CIRO NATALE;ELISA GRELLA","7;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;COMPUTER SCIENCE;POLITICAL SCIENCE;ART;ECONOMICS;MATHEMATICS;BIOLOGY;BUSINESS;GEOGRAPHY;PHYSICS;PSYCHOLOGY;SOCIOLOGY;PHILOSOPHY;CHEMISTRY;ENGINEERING;HISTORY;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE","21;20;15;13;11;11;10;10;10;10;10;10;9;8;7;6;4;1","INTERNAL MEDICINE;LAW;PATHOLOGY;ARCHAEOLOGY;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;IMMUNOLOGY;LINGUISTICS;PSYCHIATRY;HUMANITIES;LITERATURE;STATISTICS;ACOUSTICS;ECONOMIC GROWTH;EPISTEMOLOGY;FINANCE;OPERATING SYSTEM;PALEONTOLOGY;SOCIAL PSYCHOLOGY;THERMODYNAMICS;VISUAL ARTS","14;13;9;8;8;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","DISEASE;POLITICS;CONTEXT (ARCHAEOLOGY);GENE;ADVERSE EFFECT;ANXIETY;CANCER;POPULATION;WORK (PHYSICS);ARCHITECTURE;ARTIFICIAL NEURAL NETWORK;CORPORATE GOVERNANCE;CORPORATE SOCIAL RESPONSIBILITY;DURATION (MUSIC);ENERGY (SIGNAL PROCESSING);FEELING;IDENTIFICATION (BIOLOGY);IMAGE (MATHEMATICS);NATURAL (ARCHAEOLOGY);ORDER (EXCHANGE);OUTBREAK;PNEUMONIA;RESILIENCE (MATERIALS SCIENCE);SOCIAL GROUP;SUSTAINABLE DEVELOPMENT;VOCATIONAL EDUCATION;WIND POWER","5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;NOISE (VIDEO);SCHOOL-TO-WORK TRANSITION;TRANSITION (GENETICS);ABIOTIC STRESS;ANTI OXIDANT;ASPLENIA;ASYLUM SEEKER;AUTOIMMUNE DISEASE;AUTONOMIC COMPUTING;B CELL;CARDIOTOXICITY;CARIBBEAN REGION;CELLULAR DIFFERENTIATION;CENSUS;CENTER OF PRESSURE (FLUID MECHANICS);COLLECTIVE IDENTITY;CORONARY ARTERIES;CORPORATE SUSTAINABILITY;DIAPHRAGMATIC BREATHING;DYSGEUSIA;EDGE COMPUTING;EX VIVO;EXPIRATION;FACIAL RECOGNITION SYSTEM;FINGOLIMOD;FLORA (MICROBIOLOGY);FLORISTICS;GLUTATHIONE;GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM;HEALTH PROFESSIONALS;HESIOD;HISTORY OF ARCHITECTURE;HYDROGEN BOND;IMMUNOPHENOTYPING;INSTITUTIONALISM;INTERNAL MIGRATION;INVESTMENT (MILITARY);LASER SCANNING;MACROGLOBULINEMIA;MANTLE CELL LYMPHOMA;MENTAL ILLNESS;METAL FOAM;METASTASIS;MOBILE EDGE COMPUTING;MULTICENTER STUDY;NATURAL CONVECTION;NOISE CONTROL;NOISE POLLUTION;PARAMETRIC MODEL;PHARMACOVIGILANCE;PHILOLOGY;PI3K/AKT/MTOR PATHWAY;POPULATION GROWTH;POROUS MEDIUM;POSTUROGRAPHY;POWER QUALITY;PRIVACY BY DESIGN;PRIVACY POLICY;REYNOLDS NUMBER;ROOM ACOUSTICS;SHIPYARD;SOCIAL ANXIETY;SOCIAL IDENTITY THEORY;SOUND ENERGY;SUPRAMOLECULAR CHEMISTRY;SYSTEMATICS;SYSTEMIC LUPUS ERYTHEMATOSUS;TASTE DISORDER;TESTICULAR CANCER;TOCILIZUMAB;TOLERABILITY;TRANSCRIPTION FACTOR;TRANSFORMER;TURKISH ECONOMY;VERTEX (GRAPH THEORY);WALDENSTROM MACROGLOBULINEMIA","4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);ALIEN;B-CELL ACTIVATING FACTOR;CONNECTIVE TISSUE DISEASE;CURRENT TRANSFORMER;EMBRYONAL CARCINOMA;ESTROGEN RECEPTOR;FACE DETECTION;GLUTATHIONE PEROXIDASE;LYMPH NODE METASTASIS;LYMPHOPLASMACYTIC LYMPHOMA;MAMMOGRAPHY;METASTATIC BREAST CANCER;NET MIGRATION RATE;NUSSELT NUMBER;RAYLEIGH NUMBER;TRIPLE-NEGATIVE BREAST CANCER;ZINC FINGER","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";COVID-19;HUMANS;LUNG NEOPLASMS;COVID-19 NUCLEIC ACID TESTING;FEMALE;MALE;SARS-COV-2;ADULT;ANTIBODIES, MONOCLONAL, HUMANIZED;CARCINOMA, EMBRYONAL;ITALY;LAPAROSCOPY;LUNG;MIDDLE AGED;MINIMALLY INVASIVE SURGICAL PROCEDURES;PANCREATECTOMY;PANCREATICODUODENECTOMY;POINT-OF-CARE SYSTEMS;TESTICULAR NEOPLASMS","57;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","3D GEOSPATIAL MODELLING TECHNIQUES;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;ECONOMY OF KNOWLEDGE AND INNOVATION;INTERGROUP RELATIONS AND SOCIAL IDENTITY THEORIES;LABOR MARKET DYNAMICS AND INEQUALITY;PSYCHODYNAMIC PSYCHOTHERAPY AND DEVELOPMENTAL TRAUMA;SOCIETY AND ECONOMY IN ANCIENT MEDITERRANEAN CIVILIZATIONS;TRANSFORMATION OF RURAL SETTLEMENT PATTERNS IN RUSSIA;AGE-RELATED MACULAR DEGENERATION RESEARCH;ARCHITECTURAL GEOMETRY AND ARTISTIC REPRESENTATION;BREAST CANCER SCREENING TECHNOLOGY;CANCER IMMUNOTHERAPY;CONTEMPORARY ART AND AESTHETICS THEORY;CORONAVIRUS DISEASE 2019;CORPORATE SOCIAL RESPONSIBILITY AND FINANCIAL PERFORMANCE;CRITIQUE OF POLITICAL ECONOMY AND CAPITALIST DEVELOPMENT;CRYPTOGRAPHY AND ERROR-CORRECTING CODES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSTIC METHODS FOR COVID-19 DETECTION","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","EDUCATION;EMOTION RECOGNITION;IDENTIFICATION (BIOLOGY);INTERGROUP CONTACT;MIGRATIONS;RESILIENCE (MATERIALS SCIENCE);SCHOOL-TO-WORK TRANSITION;2019-20 CORONAVIRUS OUTBREAK;3D RECONSTRUCTION;ABIOTIC STRESS;AESTHETICISM;AFFECT (LINGUISTICS);AFFECTIVE COMPUTING;AGE ESTIMATION;AIRBORNE LASER SCANNING;ALERTNESS;ANOSMIA;ANTI OXIDANT;ANTIVIRAL TREATMENT;ARGUMENT (COMPLEX ANALYSIS)","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUSTMENT DEVICE;ITALIAN SCHOOL-TO-WORK;LABOUR MIGRATION;MINIMALLY INVASIVE;MOVE LABOUR;NEURAL NETWORKS;PEOPLE MOVE;SCHOOL-TO-WORK TRANSITION;ACTIVE PHARMACOVIGILANCE;AFFECT RISKADJUSTED;AGE RELATED;AGED FACIAL;AGER PRIVATUS;ANALISI DI;ANTI-OXIDANT EFFECT;AREE INTERNE;ARTERIES MINOCA;ARTIFICIAL NEURAL;ASPLENIA IMPROVING;ASSESSING ACCURACY;ASYLUM SEEKERS;AUTOMATED RECOGNITION;BASELINE DAMAGE;BEHAVIORAL SENTIMENT;BINDING MOTIF;BIO-WM TRIAL;BLACK MIRROR;BONDS TEAM;BREAST CANCER;BREATHING EXERCISES","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFLUENZA VACCINATION;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;ASPLENIC PATIENTS;DISEASE ACTIVITY;FOLLOW-UP PERIOD;INTERGROUP CONTACT;BASELINE PREDICTORS;HAND TREMOR;INFLUENZA SEASON;INTERGROUP ANXIETY;LOW DISEASE;MIGRATION FLOWS;MONTHS INCLUDED;MULTIPLE SCLEROSIS;PIK PATHWAY;RESEARCH FUNDING;TOTAL SCORE;ACUTE RESPIRATORY;AGER PUBLICUS;BASELINE NA;DISORDER QUANTIFIER;FUNDING SPEAKERS;HYRIS KIT;INFLUENZA NA;INFLUENZA VIRUSES;IOT NETWORKS;LINEAR SETS;MAXIMUM SCATTERED","9;7;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",14,0.22,6.3,7,1,1.5,0,5.5,0,0,0,7.75,0,0,6,0,0,1,4.25,4.25,4,0,0,30,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5,195.5,5.63,1,0.25,54,0,0,0,0,3,0,0,1,0,3,1,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States;Denmark","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;2;1;1;1","CLINICAL RESEARCH;AUTOIMMUNE DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEADACHES;NEUROSCIENCES;PAIN RESEARCH;PSORIASIS","2;1;1;1;1;1;1","EYE;SKIN","1;1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2021,78,12.1410256410256,1.75641025641026,0.371794871794872,0.371794871794872,0.448717948717949,1.29245283018868,1.20833333333333,1.20833333333333,1.20689655172414,0.551282051282051,5,27,10,1,20,0.35,0.13,0.01,0.26,12.92,0.838033767413704,4.6,0.602564102564103,0.871794871794872,0.505,0.311,0.307,0.288,"FRANCESCO PASTORE;SAVERIO CINIERI;ALLAN WEBSTER;SANGEETA KHORANA;FRANCESCO RASPAGLIESI;GABRIELE PONTILLO;FLORIANA MORGILLO;CIRO GALLO;GIOVANNI SCAMBIA;MICHELE ORDITURA;VANDA SALUTARI;DOMENICA LORUSSO;RENATO FRANCO;ROSSELLA LAURIA;SANDRO PIGNATA;FRANCESCO PERRONE;MARCO MONTELLA;ALFONSO MARINO;ALESSANDRA BOLOGNA;RAFAEL BORRÁS","8;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","FRANCESCO PASTORE;ORNELLA CIRILLO;GABRIELE PONTILLO;ALLAN WEBSTER;SANGEETA KHORANA;GIULIA SCALERA;JIE CHEN;GIOVANNI ZINI;CARMELA ILENIA AMATO;MARIA ANTONIETTA SBORDONE;ALFONSO MARINO;ROBERTA ANGARI;CARLA LANGELLA;ADRIANA ROSSI;PAOLO PARISO;SARA GONIZZI BARSANTI;EMÉRANCIA RAHARISOA;ABDUL QAYOOM;FAISAL RASOOL;MONICA D’AURIA","3.08;1.5;1.33;1.33;1.33;1;1;1;1;1;0.83;0.83;0.83;0.83;0.83;0.83;0.5;0.5;0.5;0.5","FRANCESCO PASTORE;GABRIELE PONTILLO;FLORIANA MORGILLO;CIRO GALLO;MICHELE ORDITURA;RENATO FRANCO;MARCO MONTELLA;ALFONSO MARINO;EMÉRANCIA RAHARISOA;ORNELLA CIRILLO;ROBERTA ANGARI;GIANLUCA PELLINO;CARLA LANGELLA;ELISABETTA SIGNORIELLO;ADRIANA ROSSI;PAOLO PARISO;SEBASTIANO COSTA;ESTER CATALANO;SILVERIO PERROTTA;AGNESE COSCETTA","8;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","FRANCESCO PASTORE;ORNELLA CIRILLO;GABRIELE PONTILLO;GIULIA SCALERA;GIOVANNI ZINI;CARMELA ILENIA AMATO;MARIA ANTONIETTA SBORDONE;ALFONSO MARINO;ROBERTA ANGARI;CARLA LANGELLA;ADRIANA ROSSI;PAOLO PARISO;SARA GONIZZI BARSANTI;EMÉRANCIA RAHARISOA;MICHELA CARLOMAGNO;CLAUDIO GAMBARDELLA;CLAUDIA CENNAMO;ROBERTO LIBERTI;PAOLO MONTALDO;ESTER CATALANO","3.08;1.5;1.33;1;1;1;1;0.83;0.83;0.83;0.83;0.83;0.83;0.5;0.5;0.5;0.5;0.5;0.38;0.33","SAVERIO CINIERI;CIRO GALLO;FRANCESCO PERRONE;DOMENICA LORUSSO;FRANCESCO RASPAGLIESI;GIOVANNI SCAMBIA;MICHELE ORDITURA;ROSSELLA LAURIA;SANDRO PIGNATA;VANDA SALUTARI;ALESSANDRA BOLOGNA;ANGIOLO GADDUCCI;ANTONIO ARDIZZOIA;ARISTOTELIS BAMIAS;CARMELA PISANO;CRISTIANA SESSA;DANIELA SAMBATARO;ELENA ZAFARANA;EMMANUEL GUARDIOLA;ENRICO BREDA","221;214;214;201;201;201;201;201;201;201;194;194;194;194;194;194;194;194;194;194","MICHELE ORDITURA;SEBASTIANO COSTA;C. LOGUERCIO;MARIO MUSTILLI;AGNESE COSCETTA;ALDO MINARDO;ENIS CERRI;ESTER CATALANO;LUIGI ZENI;NUNZIO CENNAMO;ROBERTO ALFANO;DANIELE MAURO;FRANCESCO CICCIA;FERDINANDO DE VITA;DANIELE MASARONE;GIUSEPPE LIMONGELLI;FRANCESCO GANGI;LUCIA MICHELA DANIELE;NICOLA VARRONE;ELISABETTA SIGNORIELLO","201;147;144;77;55;55;55;55;55;55;53;44;44;40;35;35;31;31;31;29","FRANCESCO PASTORE;MICHELE ORDITURA;GABRIELE PONTILLO;ADRIANO STINCA;AGNESE COSCETTA;ALDO MINARDO;ALFONSO MARINO;ENIS CERRI;ESTER CATALANO;GIANLUCA PELLINO;LUIGI ZENI;NUNZIO CENNAMO;ORNELLA CIRILLO;PAOLO MONTALDO;PAOLO PARISO;ROBERTA ANGARI;SEBASTIANO COSTA;ADRIANA BRANCACCIO;ALESSANDRA DI LIELLO;ANDREA CUSANO","8;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;COMPUTER SCIENCE;ECONOMICS;BUSINESS;BIOLOGY;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;ENGINEERING;GEOGRAPHY;HISTORY;PHYSICS;CHEMISTRY;SOCIOLOGY;ART;PHILOSOPHY;GEOLOGY;MATERIALS SCIENCE","41;24;16;15;14;14;12;11;10;8;8;8;7;7;6;6;4;4","INTERNAL MEDICINE;PATHOLOGY;ARCHAEOLOGY;ONCOLOGY;SURGERY;PEDIATRICS;LAW;ARCHITECTURAL ENGINEERING;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;DEMOGRAPHIC ECONOMICS;ECOLOGY;MATHEMATICAL ANALYSIS;PALEONTOLOGY;PURE MATHEMATICS;ACOUSTICS;ALGORITHM;COMPUTER VISION;ENVIRONMENTAL HEALTH;FINANCE;IMMUNOLOGY;LABOUR ECONOMICS;NEUROSCIENCE;NURSING;SOCIAL PSYCHOLOGY;STATISTICS;VIROLOGY;VISUAL ARTS","26;12;11;8;8;7;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","DISEASE;CANCER;GENE;CLOTHING;POPULATION;CHEMOTHERAPY;CLINICAL TRIAL;GOVERNMENT (LINGUISTICS);OUTBREAK;PRODUCTION (ECONOMICS);PSYCHOLOGICAL INTERVENTION;RETROSPECTIVE COHORT STUDY;SAMPLE (MATERIAL);SUSTAINABILITY;TEXTILE;TOURISM;ACTION (PHYSICS);ALTERNATIVE MEDICINE;ANTIBODY;ASYMPTOMATIC;BACTERIA;CHILD HEALTH;CHINA;DIABETES MELLITUS;DIMENSION (GRAPH THEORY);DISTRIBUTION (MATHEMATICS);HEALTH CARE;HEART FAILURE;IDENTIFICATION (BIOLOGY);IMAGE (MATHEMATICS);MESOTHELIOMA;MULTIPLE SCLEROSIS;OPTICAL FIBER;POISON CONTROL;PRODUCT (MATHEMATICS);PROPENSITY SCORE MATCHING;PUBLIC HEALTH;RANDOMIZED CONTROLLED TRIAL;ROBOT;SOCIAL GROUP;SOCIAL SUPPORT;SPECIES RICHNESS;TEXTILE DESIGN;TRANSLATIONAL RESEARCH;VALUE (MATHEMATICS)","11;7;5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;CDKN2A;CLINICAL ENDPOINT;FIBER OPTIC SENSOR;FINGOLIMOD;FLORA (MICROBIOLOGY);INSULIN RESISTANCE;OVARIAN CANCER;RITUXIMAB;SOCIAL IDENTITY THEORY;VASCULAR PLANT;WESTERN BLOT;ALIEN SPECIES;ALLELE;ANGIOTENSIN II;BEVACIZUMAB;BREAST CANCER;BRILLOUIN SCATTERING;CARDIAC FUNCTION CURVE;CARDIOTOXICITY;CD20;CENSUS;CHOLECYSTITIS;CISPLATIN;COLORECTAL CANCER;COMMUNITY RESILIENCE;CROHN'S DISEASE;CRONBACH'S ALPHA;DIASTOLE;DYSBIOSIS;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;EX VIVO;EXPLORATORY FACTOR ANALYSIS;FASHION DESIGN;FASHION INDUSTRY;FATTY LIVER;FLEXIBLE MANUFACTURING SYSTEM;GAMBLING DISORDER;GEMCITABINE;HAZARD RATIO;HEALTH DEPARTMENT;HOSPITAL PHARMACY;HOSPITALITY;HOUGH TRANSFORM;HUMAN FACTORS AND ERGONOMICS;HYPERTENSIVE HEART DISEASE;IMMUNOTHERAPY;IMPULSE CONTROL DISORDER;INFLAMMASOME;INJURY PREVENTION;INTERLEUKIN;INTERPOLATION (COMPUTER GRAPHICS);INTRACLASS CORRELATION;IRON DEFICIENCY;IRON-DEFICIENCY ANEMIA;LEAN BODY MASS;METABOLIC SYNDROME;MICROCYTIC ANEMIA;MICROPERIMETRY;MOTION PLANNING;MOTOR NEURON;MULTICENTER STUDY;NATALIZUMAB;NEONATAL ENCEPHALOPATHY;OMNIDIRECTIONAL ANTENNA;OVERSAMPLING;PACLITAXEL;PERSPECTIVE-TAKING;PHARMACIST;PHASES OF CLINICAL RESEARCH;PLACEBO;POLYMERASE;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;PROTOCOL (SCIENCE);PUPILLOMETRY;RACE TO THE BOTTOM;RELAPSING REMITTING;REPRESENTATION (POLITICS);RETURNS TO SCALE;ROBOTIC HAND;SAMPLING (SIGNAL PROCESSING);SENSORINEURAL HEARING LOSS;SEROLOGY;SICKLE CELL ANEMIA;SPINAL MUSCULAR ATROPHY;SUSTAINABLE DESIGN;TACTILE SENSOR;TARGETED THERAPY;TAX POLICY;TOURISM GEOGRAPHY;TRANSCRIPTION FACTOR;UNDERACTUATION;VALSARTAN;WEIGHT LOSS","7;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);OCRELIZUMAB;AIM2;ALIEN;ANTISOCIAL PERSONALITY DISORDER;BRCA MUTATION;CARBOPLATIN;CETUXIMAB;CULTURAL TOURISM;CYTOREDUCTIVE SURGERY;DIASTOLIC HEART FAILURE;DISTRIBUTED ACOUSTIC SENSING;DOMESTIC VIOLENCE;EGFR INHIBITORS;EMPATHIC CONCERN;GRADED-INDEX FIBER;HEART FAILURE WITH PRESERVED EJECTION FRACTION;ILEITIS;IPILIMUMAB;KRAS;MICROSATELLITE;OFATUMUMAB;PEMBROLIZUMAB;POLARIZATION-MAINTAINING OPTICAL FIBER;POLY ADP RIBOSE POLYMERASE;REPRESSOR;SACUBITRIL;SACUBITRIL, VALSARTAN;STEATOHEPATITIS;TRANSFERRIN SATURATION;TRASTUZUMAB","7;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;ILEUM;JOINTS;MALE;MIDDLE AGED;ANTI-BACTERIAL AGENTS;BRAIN DISEASES;HEART FAILURE;ILEITIS;INFANT, NEWBORN, DISEASES;LIVER;NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;NON-ALCOHOLIC FATTY LIVER DISEASE;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BEVACIZUMAB;CALCIUM-BINDING PROTEINS;CARBOPLATIN","63;15;7;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3","IMPACTS OF COVID-19 ON GLOBAL ECONOMY AND MARKETS;INTERDISCIPLINARY STUDY OF FASHION AND CLOTHING;FINANCING OF HEALTH CARE SYSTEMS AND UNIVERSAL COVERAGE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MOLECULAR MECHANISMS OF RETINAL DEGENERATION AND REGENERATION;NEONATAL BRAIN INJURY AND DEVELOPMENTAL CONSEQUENCES;THE IMPACT OF CREATIVE INDUSTRIES ON URBAN DEVELOPMENT;VASCULAR FLORA OF MEDITERRANEAN EUROPE AND NORTH AFRICA;ADDITIVE MANUFACTURING AND 3D PRINTING TECHNOLOGIES;CANCER IMMUNOTHERAPY;CONCEPTUALIZATION AND MEASUREMENT OF TIME PERSPECTIVE;COOPETITION IN BUSINESS NETWORKS AND INNOVATION;CORONAVIRUS DISEASE 2019 RESEARCH;CORPORATE SOCIAL RESPONSIBILITY AND FINANCIAL PERFORMANCE;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","PANDEMIC;FASHION;2019-20 CORONAVIRUS OUTBREAK;CO-CREATION;SAMPLE (MATERIAL);TEXTILE;BREAST CANCER;CHILD HEALTH;CLINICAL ENDPOINT;CLOTHING;DESIGN;DESIGN THINKING;DISTRIBUTED SENSING;ECONOMIC EFFECTS;FLORA (MICROBIOLOGY);IDENTIFICATION (BIOLOGY);LABOR MARKETS;LOW- AND MIDDLE-INCOME COUNTRIES;MALIGNANT PLEURAL MESOTHELIOMA;NEONATAL ENCEPHALOPATHY","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PATIENTS TREATED;ASYMPTOMATIC SOCCER;ATTRIBUTES ANALYSIS;CARBOPLATIN-BASED DOUBLET;CENTRAL AMERICA;CLINICAL PRACTICE;COMMUNITY IDENTIFICATION;DAY UPDATES;EMPLOYMENT LABOUR;GENDER EQUALITY;GENE THERAPY;HEART FAILURE;HOSPITAL PHARMACY;LABOUR MARKET;LABOUR MARKETS;MALIGNANT PLEURAL;MARKET IMPACT;MESOTHELIOMA MPM;MPM PRELIMINARY;MULTICENTER TRANSLATIONAL;OVARIAN CANCER;PHASE II;PIVOTAL MULTICENTER;PLEURAL MESOTHELIOMA;PRELIMINARY RESULTS;PRODUCT ATTRIBUTES;RESEARCH PROJECT;SOCCER PLAYER;SOUTHERN EUROPE;STUDY HARD","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;CARDIAC ADRS;GRANTFUNDING INSTITUTION;RESEARCH GRANTFUNDING;DEGLI STUDI;FOLD INDUCTION;INDUCTION VERSUS;PERSONAL FEES;ADVISORY COMMITTEES;ADVISORYCONSULTANCY RESEARCH;COMMUNITY IDENTIFICATION;CONSULTING FEES;ENTITYS BOARD;EUROPEAN COUNTRIES;UNIVERSITÀ DEGLI;UPPER SECONDARY;ANNUAL TCD;ARAMCHOL MG;AUDITORY CORTEX;BAP AURKA;CAMPANIA LUIGI;CLINICAL PRACTICE;CONFIDENCE INTERVAL;CONTAINMENT MEASURES;DELLA CAMPANIA;FORMPREFIXMMLMOMMLMINMMLMIMMLMO STRETCHYFALSE;GENE THERAPY;GOVERNMENT CONTAINMENT;HEART FAILURE;INSTRUMENTAL VARIABLE","11;8;8;8;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",14,0.18,14.72,24.25,1,0,0,5,0,0,0,31.75,0,0,22,0,0,2,5.75,14.25,5.5,0,0,30.75,30.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4,191.5,3.96,4,1,73.75,0,0,1,0,2,0,1,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Portugal;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;NEUROSCIENCES;AGING;AUTOIMMUNE DISEASE;BRAIN DISORDERS;LUNG;MYASTHENIA GRAVIS;NEURODEGENERATIVE;PARKINSON'S DISEASE;PREVENTION;RARE DISEASES","4;4;2;2;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2022,75,11.1066666666667,2.37333333333333,0.533333333333333,0.413333333333333,0.546666666666667,1.63302752293578,1.33333333333333,1.40909090909091,1.36666666666667,0.706666666666667,8,11,3,11,15,0.15,0.04,0.15,0.2,2.6,0.291257509345632,5.6260162601626,0.36,0.72,0.519,0.312,0.398,0.334,"MARIA ANTONIETTA SBORDONE;ORONZIO MANCA;BERNARDO BUONOMO;ROBERTA ALFIERI;FRANCESCO NATALE;ANTONIO MANCINI;IPPOLITA ALTOBELLI;RICCARDO MOLINARI;DANIELE MASARONE;EDUARDO BOSSONE;GIUSEPPE LIMONGELLI;MASSIMO IACOVIELLO;GIOVANNI CIMMINO;FRANCESCO LOFFREDO;ANGELA SCIACQUA;VINCENZO TRIGGIANI;FRANCESCO PASTORE;PASQUALE PERRONE FILARDI;SIMONA COVINO;ANTONIO CITTADINI","6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","FRANCESCO PASTORE;MARIA ANTONIETTA SBORDONE;GIANNI MONTAGNA;ORONZIO MANCA;BERNARDO BUONOMO;CHIARA SCARPITTI;FRANCESCA LA ROCCA;ÖMER TUĞSAL DORUK;GAIA SALVATORI;GIOVANNA D’ALFONSO;VITO NAPOLITANO;ILARIA CRISTOFARO;DOMENICO CRISPINO;MARIA D'UONNO;ROBERTA ALFIERI;FRANCESCO NATALE;IPPOLITA ALTOBELLI;RICCARDO MOLINARI;GIOVANNI CIMMINO;SIMONA COVINO","2.17;2;1.5;1.5;1.5;1.5;1;1;1;1;1;1;1;1;0.7;0.7;0.7;0.7;0.7;0.7","MARIA ANTONIETTA SBORDONE;ORONZIO MANCA;ROBERTA ALFIERI;FRANCESCO NATALE;IPPOLITA ALTOBELLI;RICCARDO MOLINARI;DANIELE MASARONE;GIUSEPPE LIMONGELLI;GIOVANNI CIMMINO;FRANCESCO LOFFREDO;FRANCESCO PASTORE;SIMONA COVINO;ENRICA PEZZULLO;SILVERIO PERROTTA;PAOLO CALABRÒ;ALFONSO MARINO;ALESSANDRA DE LUCA;FRANCESCO CICCIA;GIANLUCA PELLINO;PAOLO PARISO","6;6;5;5;5;5;5;5;5;5;5;5;4;4;3;2;2;2;2;2","FRANCESCO PASTORE;MARIA ANTONIETTA SBORDONE;ORONZIO MANCA;CHIARA SCARPITTI;FRANCESCA LA ROCCA;GAIA SALVATORI;GIOVANNA D’ALFONSO;VITO NAPOLITANO;ILARIA CRISTOFARO;DOMENICO CRISPINO;MARIA D'UONNO;ROBERTA ALFIERI;FRANCESCO NATALE;IPPOLITA ALTOBELLI;RICCARDO MOLINARI;GIOVANNI CIMMINO;SIMONA COVINO;ALFONSO MARINO;PAOLO PARISO;FRANCESCO LOFFREDO","2.17;2;1.5;1.5;1;1;1;1;1;1;1;0.7;0.7;0.7;0.7;0.7;0.7;0.67;0.67;0.66","ANGELA SCIACQUA;ANTONIO CITTADINI;ANTONIO MANCINI;DANIELE MASARONE;EDUARDO BOSSONE;GIUSEPPE LIMONGELLI;MASSIMO IACOVIELLO;PASQUALE PERRONE FILARDI;VINCENZO TRIGGIANI;FABIO SPAGNOLO;NICOLA SPAGNOLO;ROGEMAR MAMON;YIYANG CHEN;CIRO MAIELLO;FRANCESCO CACCIATORE;ALBERTO M. MARRA;ANDREA SALZANO;MICHELE ARCOPINTO;PAOLA GARGIULO;ROBERTA D’ASSANTE","41;41;41;41;41;41;41;41;41;38;38;38;38;36;36;34;34;34;34;34","DANIELE MASARONE;GIUSEPPE LIMONGELLI;NICOLA SPAGNOLO;FRANCESCO SELVAGGI;GIANLUCA PELLINO;SILVERIO PERROTTA;ALFONSO MARINO;F. COLOMBO;FRANCESCO GIUDICI;FRANCESCO SIONNE;LUCIO SELVAGGI;PAOLO PARISO;MAURO PINTO;FRANCESCO CICCIA;FRANCESCO PASTORE;DANIELE GRANATA;GIOVANNI SALZILLO;MASSIMILIANO RAK;SAVERIO SCIANGUETTA;MARIA VITTORIÅ MONTEMURRO","41;41;38;28;28;24;14;14;14;14;14;14;10;8;8;7;7;7;7;6","ORONZIO MANCA;MARIA ANTONIETTA SBORDONE;DANIELE MASARONE;FRANCESCO PASTORE;GIUSEPPE LIMONGELLI;SILVERIO PERROTTA;A. PRISCO;ALESSANDRA DE LUCA;ALFONSO MARINO;CARMELA ILENIA AMATO;CHIARA SCARPITTI;FRANCESCO CICCIA;FRANCESCO SELVAGGI;GIANLUCA PELLINO;PAOLO PARISO;ADRIANA ROSSI;ALDO MINARDO;ANNA LAURA BARALDI;ANTONIO MARTE;CAMELIA CHIVĂRAN","6;6;5;5;5;4;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;COMPUTER SCIENCE;BIOLOGY;BUSINESS;ECONOMICS;ENGINEERING;ART;PHYSICS;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;GEOGRAPHY;MATERIALS SCIENCE;HISTORY;MATHEMATICS;PHILOSOPHY;CHEMISTRY;ENVIRONMENTAL SCIENCE;GEOLOGY","34;20;15;14;14;14;12;12;12;12;11;8;7;5;5;5;2;2;2","INTERNAL MEDICINE;LAW;SURGERY;ECOLOGY;PATHOLOGY;THERMODYNAMICS;ARCHAEOLOGY;CARDIOLOGY;MECHANICAL ENGINEERING;PROGRAMMING LANGUAGE;AESTHETICS;ARTIFICIAL INTELLIGENCE;ECONOMIC GROWTH;IMMUNOLOGY;LITERATURE;MACHINE LEARNING;RADIOLOGY;VISUAL ARTS;ENVIRONMENTAL HEALTH;FINANCE;MECHANICS;PEDIATRICS;SOCIAL SCIENCE","23;10;10;8;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4","DISEASE;GENE;SUSTAINABILITY;HEART FAILURE;POPULATION;VALUE (MATHEMATICS);BLOOD PRESSURE;CLOTHING;COGNITION;HEALTH CARE;POLITICS;THERMAL;WORK (PHYSICS);AUTOMOTIVE INDUSTRY;CANCER;CHEMOTHERAPY;CHEST PAIN;CONVECTION;DIABETES MELLITUS;DISCIPLINE;FUNDAMENTAL HUMAN NEEDS;GUT FLORA;INTERPRETATION (PHILOSOPHY);MALIGNANCY;METAL;NARRATIVE;NEUROSURGERY;NUTRACEUTICAL;POWER (PHYSICS);PROCESS (COMPUTING);PRODUCTION (ECONOMICS);QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;RENAL FUNCTION;SPACE (PUNCTUATION);THALASSEMIA;THERMAL ENERGY STORAGE;THERMOELECTRIC EFFECT","6;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EJECTION FRACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);METAL FOAM;FAST FASHION;GENERATOR (CIRCUIT THEORY);HEART RATE;NATURAL CONVECTION;THERMOELECTRIC GENERATOR;2019-20 CORONAVIRUS OUTBREAK;ABDOMINAL AORTIC ANEURYSM;ADALIMUMAB;ANTEROGRADE AMNESIA;AORTIC ANEURYSM;ARDS;ARTERIAL STIFFNESS;BIPOLAR DISORDER;BLOATING;BOWEL MANAGEMENT;BRILLOUIN SCATTERING;CARBAPENEM;CISPLATIN;CLINICAL ENDPOINT;CONSTRUCTIVE;CONVECTIVE HEAT TRANSFER;CREATURES;CROHN'S DISEASE;DEMENTIA;DEMOCRACY;DEVOPS;ECHOGENICITY;ESCHERICHIA COLI;ETANERCEPT;EUROPEAN COMMISSION;FASHION INDUSTRY;FETUS;FLAT ROOF;FLUENT;FOOD ALLERGY;FRACTION OF INSPIRED OXYGEN;FUMAROLE;GENOTYPE;GLOBAL ASSESSMENT OF FUNCTIONING;HEAT FLUX;IDEOLOGY;IMMUNOTHERAPY;INSULIN RESISTANCE;INTIMA-MEDIA THICKNESS;LACTOBACILLUS;LAVA;LITHOSPHERE;MACROGLOBULINEMIA;MARKOV MODEL;MEMBER STATES;METASOMATISM;NOISE (VIDEO);OPEN LABEL;OVARIAN CANCER;PALSY;PERICARDIECTOMY;PHASE-CHANGE MATERIAL;PHENOTYPE;PNEUMOPERICARDIUM;POLYMERASE;POLYMERASE CHAIN REACTION;POROUS MEDIUM;PSORIATIC ARTHRITIS;PSYCHOEDUCATION;RETROGRADE AMNESIA;RIFT;SECURITY SERVICE;SKULL FRACTURE;SOFTWARE DEVELOPMENT;SPINAL DYSRAPHISM;SUSTAINABLE DESIGN;TELEMEDICINE;TRANSIENT GLOBAL AMNESIA;TRANSITION (GENETICS);TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;VERNACULAR ARCHITECTURE;WALDENSTROM MACROGLOBULINEMIA","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);BASDAI;BELL'S PALSY;CAREGIVER BURDEN;COW'S MILK ALLERGY;CROHN DISEASE;CYTOREDUCTIVE SURGERY;DIGITAL POLYMERASE CHAIN REACTION;EAST AFRICAN RIFT;GENOTYPE-PHENOTYPE DISTINCTION;GOLIMUMAB;IFOSFAMIDE;KLEBSIELLA PNEUMONIAE;LACTOBACILLUS RHAMNOSUS;MANTLE PLUME;MEMBER STATE;MILK ALLERGY;ORAL IMMUNOTHERAPY;POLY ADP RIBOSE POLYMERASE;PRENATAL DIAGNOSIS;REPRESENTATIVE DEMOCRACY;RIFT ZONE;SOFTWARE DEVELOPMENT PROCESS;SOFTWARE SECURITY ASSURANCE;SPECKLE TRACKING ECHOCARDIOGRAPHY;TELEHEALTH;USTEKINUMAB;VO2 MAX","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ADULT;BONE NEOPLASMS;ITALY;OSTEOSARCOMA;PNEUMONIA;RESPIRATORY DISTRESS SYNDROME;ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B;FEMALE;HEART FAILURE;NEUROGENIC BOWEL;PROSPECTIVE STUDIES;REGISTRIES;RETROSPECTIVE STUDIES;STROKE VOLUME;VENTRICULAR DYSFUNCTION, RIGHT;ADOLESCENT;CHILD;CONSTIPATION","66;9;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2","CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;INCOME INEQUALITY AND POVERTY DYNAMICS;LABOR MARKET DYNAMICS AND INEQUALITY;TERRITORIAL GOVERNANCE AND ENVIRONMENTAL PARTICIPATION;THERMAL ENERGY STORAGE WITH PHASE CHANGE MATERIALS;THERMOELECTRIC MATERIALS;;3D GEOSPATIAL MODELLING TECHNIQUES;ARCHAEOASTRONOMY AND CULTURAL LANDSCAPES;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BUILDING ENERGY EFFICIENCY AND THERMAL COMFORT OPTIMIZATION;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CONCEPTUALIZING THE CIRCULAR ECONOMY AND SUSTAINABLE SUPPLY CHAINS;CONTEMPORARY ART AND AESTHETICS THEORY;CRAFTIVISM AND HANDICRAFT CULTURE;CRYPTOGRAPHY AND ERROR-CORRECTING CODES;CULTURAL TRANSFER AND ARTISTIC EXCHANGE IN EUROPE;CYBERBIOSECURITY AND LEGAL IMPLICATIONS OF AI TECHNOLOGY;DEVELOPMENT OF NARRATIVE IDENTITY IN EMERGING ADULTHOOD","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","VALUE (MATHEMATICS);CARDIOPULMONARY EXERCISE TESTING;DISCIPLINE;ENERGY HARVESTING;FAST FASHION;FUNDAMENTAL HUMAN NEEDS;HEAT TRANSFER;INSULIN SIGNALING;NUTRACEUTICAL;PANDEMIC;PHASE CHANGE MATERIALS;SUSTAINABILITY;THERMAL CONDUCTIVITY ENHANCEMENT;THERMAL ENERGY STORAGE;THERMOELECTRIC;THERMOELECTRIC GENERATOR;;2019-20 CORONAVIRUS OUTBREAK;3D MODEL;3D PRINTED","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","ADULT PATIENTS;TOSCA REGISTRY;AREAL PROJECT;AUTOMOTIVE LINES;CELL DISEASE;CONFRONTING UNRELATED;DIABETES MELLITUS;DIGITAL PLATFORMS;ENERGY STORAGE;EXHAUST AUTOMOTIVE;FASHION CONFRONTING;HEART FAILURE;INTIMA MEDIA;MATERIALS VIABLE;METAL FOAM;MULTICENTRE STUDY;NUMERICAL STUDY;PARAMETERS ENHANCEMENT;PERFORMANCE PARAMETERS;RE-INVENT PEOPLE;REALITY APPLICATION;SICKLE CELL;SOUTHERN ITALY;THERMAL ENERGY;THERMOELECTRIC GENERATOR;UNRELATED SECTORS;VIABLE RELATIONSHIPS;VIRTUAL REALITY;ABCBPGLYCOPROTEIN EXPRESSION;ABDOMINAL AORTIC","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","POLYCYSTIC KIDNEY;PUBMED SCOPUS;KIDNEY INT;KIDNEY DISEASE;AUTOSOMAL DOMINANT;CORRECTION APPEARS;DOMINANT POLYCYSTIC;PUBLISHED CORRECTION;CYSTS NORMAL;DE NOVO;HARRIS PC;HTN YR;PKD GENES;HTTPSDOIORGASNCROSSREF PUBMED;NEPHROL -HTTPSDOIORGASNCROSSREF;RENALLIVER CYSTS;SOC NEPHROL;GOOGLE SCHOLARSS;INT PUBLISHED;PGP PATIENTS;PKD VARIANTS;AEROBIC TRAINING;ARTERIAL STIFFNESS;NORMAL EGFR;PKD PAT;PKD VARIANT;RENAL DISEASE;TKV CC;TORRES VE;VERNACULAR ARCHITECTURE","22;21;12;11;9;9;9;9;8;8;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5",11,0.15,3.02,4.5,0,0,0,0,0,0,0,4.5,0,0,4.5,0,0,1.5,1,4.5,2,0,0,18,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,6,1006,3.7,4,1,176,0,0,0,0,3,0,0,1,0,3,1,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Italy;Germany;United States","3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);AUTOIMMUNE DISEASE;BRAIN DISORDERS;DEMENTIA;DIGESTIVE DISEASES;INFLAMMATORY BOWEL DISEASE;LUNG;LUNG CANCER;NEURODEGENERATIVE;NEUROSCIENCES;PATIENT SAFETY;RARE DISEASES","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","2;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","3;1;1;1","HEAD AND NECK CANCER;LUNG CANCER;PHARYNGEAL CANCER","1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2023,52,8.09615384615385,1.75,0.423076923076923,0.307692307692308,0.442307692307692,1.19736842105263,1,1.23076923076923,0.958333333333333,0.75,11,12,5,2,7,0.23,0.1,0.04,0.13,0.98,0.223762085221504,5.43243243243243,0.211538461538462,0.75,0.479,0.107,0.283,0.219,"GIOVANNI CIMMINO;FLORIANA MORGILLO;ENRICA PEZZULLO;RICCARDO MOLINARI;MASSIMILIANO MASULLO;JOSEP TABERNERO;CONCETTA TUCCILLO;JULIEN TAÏEB;ELENA ÉLEZ;CARMINIA MARIA DELLA CORTE;P. MIGLIOZZI;FRANCESCO GANGI;PAOLO GOLINO;LUCIA ALTUCCI;MADDALENA CASALE;GENNARO MIELE;NOEMI MOLLO;SILVERIO PERROTTA;UGO CHIANESE;PAOLO CHIODINI","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORRADO CASTAGNARO;CLAUDIO VACANTI;MARIA ANTONIETTA SBORDONE;MARTINI;LUCA SARTI;ILARIA CRISTOFARO;SANDRA COPPOLA;IUCANA MOUCO;NICHOLAS BORTOLOTTI;CAROLINA FRANCESCA MARIA DAVALLI;GIORGIA OGGIANO;GIOVANNI CIMMINO;FRANCESCO GANGI;FRANCESCO SIELO;MARIO TRIFUOGGI;MASSIMILIANO MASULLO;LUIGI MAFFEI;RICCARDO MOLINARI;FLORIANA MORGILLO;ENRICA PEZZULLO","1;1;1;1;1;1;1;1;1;1;1;0.64;0.58;0.5;0.5;0.45;0.45;0.41;0.36;0.35","GIOVANNI CIMMINO;FLORIANA MORGILLO;ENRICA PEZZULLO;MASSIMILIANO MASULLO;CONCETTA TUCCILLO;FRANCESCO GANGI;PAOLO GOLINO;LUCIA ALTUCCI;MADDALENA CASALE;SILVERIO PERROTTA;PAOLO CHIODINI;ANTONELLO SICA;W. IDRISSI IBNSALIH;LUIGI MAFFEI;FRANCESCO S. LOFFREDO;M. R. MUSONE;FRANCESCO SIELO;DONATO CATAPANO;SALVATORE CARLEO;CARLO GAROFALO","5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CORRADO CASTAGNARO;CLAUDIO VACANTI;MARIA ANTONIETTA SBORDONE;MARTINI;LUCA SARTI;ILARIA CRISTOFARO;SANDRA COPPOLA;IUCANA MOUCO;NICHOLAS BORTOLOTTI;CAROLINA FRANCESCA MARIA DAVALLI;GIORGIA OGGIANO;GIOVANNI CIMMINO;FRANCESCO GANGI;FRANCESCO SIELO;MASSIMILIANO MASULLO;LUIGI MAFFEI;FLORIANA MORGILLO;ENRICA PEZZULLO;SALVATORE CARLEO;NICOLA SPAGNOLO","1;1;1;1;1;1;1;1;1;1;1;0.64;0.58;0.5;0.45;0.45;0.36;0.35;0.33;0.33","LUCIA ALTUCCI;ROSARIA BENEDETTI;UGO CHIANESE;EDUARDO SOMMELLA;EMANUELA SALVIATI;GIUSEPPE PAOLISSO;LUCIA SCISCIOLA;MANUELA GIOVANNA BASILICATA;MICHELANGELA BARBIERI;PIETRO CAMPIGLIA;VICKY CAPONIGRO;FRANCESCO GANGI;MARIA COSCIA;NICOLA VARRONE;EDOARDO MAZZUCCHI;ENRICO POLA;FABRIZIO PIGNOTTI;GIANLUCA GALIERI;GIOVANNI SABATINO;GIUSEPPE LA ROCCA","11;11;11;9;9;9;9;9;9;9;9;7;6;6;4;4;4;4;4;4","LUCIA ALTUCCI;ROSARIA BENEDETTI;FRANCESCO GANGI;ENRICO POLA;LUIGI AURELIO NASTO;AMELIA TREMATERRA;FORTUNATO CIARDELLO;GINO IANNACE;GIOVANNI CIMMINO;MADDALENA CASALE;SILVERIO PERROTTA;G. DE GREGORIO;IMMACOLATA TARTAGLIONE;L. CORAGGIO;N. ITACO;PAOLO MONTALDO;SANDRA COPPOLA;ANDREA APROVITOLA;ANDREINA CARBONE;ANTIMO GLORIOSO","11;11;7;4;4;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1","GIOVANNI CIMMINO;FRANCESCO GANGI;LUCIA ALTUCCI;LUIGI MAFFEI;M. R. MUSONE;MADDALENA CASALE;MASSIMILIANO MASULLO;PAOLO CHIODINI;ROSARIA BENEDETTI;SILVERIO PERROTTA;W. IDRISSI IBNSALIH;AMELIA TREMATERRA;ANDREA APROVITOLA;ANDREINA CARBONE;ANTIMO GLORIOSO;ENRICO POLA;FEDERICA PORCELLI;FORTUNATO CIARDELLO;FRANCESCA SIMONELLI;G. DE GREGORIO","5;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;COMPUTER SCIENCE;BIOLOGY;ENGINEERING;HISTORY;PHYSICS;POLITICAL SCIENCE;ART;BUSINESS;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;ECONOMICS;GEOGRAPHY;GEOLOGY;MATERIALS SCIENCE","24;13;12;10;9;8;8;7;7;7;7;7;7;6;6;5;2;1","INTERNAL MEDICINE;ARCHAEOLOGY;INTENSIVE CARE MEDICINE;LAW;FINANCE;ONCOLOGY;SURGERY;CARDIOLOGY;ECOLOGY;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;LINGUISTICS;MARKETING;AEROSPACE ENGINEERING;ARTIFICIAL INTELLIGENCE;ASTRONOMY;BIOCHEMISTRY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;GEOMETRY;IMMUNOLOGY;LITERATURE;NEUROSCIENCE;OPTICS;PALEONTOLOGY;PHARMACOLOGY;RADIOLOGY","20;8;7;7;6;6;6;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CANCER;CLINICAL TRIAL;CONTEXT (ARCHAEOLOGY);DISEASE;GENE;CHEMOTHERAPY;IMMUNE SYSTEM;POPULATION;BLOOD PRESSURE;COMPUTATIONAL FLUID DYNAMICS;CORPORATE GOVERNANCE;DIVERSITY (POLITICS);DNA;EXCELLENCE;FUNCTION (BIOLOGY);GALAXY;HEART FAILURE;INCIDENCE (GEOMETRY);LUNG CANCER;LYMPHOMA;NARRATIVE;NATURAL (ARCHAEOLOGY);NEUTRINO;OUTBREAK;PAYMENT;PERSPECTIVE (GRAPHICAL);POLITICS;PRODUCT (MATHEMATICS);RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;SENSITIVITY (CONTROL SYSTEMS);VALUE (MATHEMATICS)","4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;BEVACIZUMAB;COLORECTAL CANCER;DNA DAMAGE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PHASES OF CLINICAL RESEARCH;ARTERIAL STIFFNESS;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BETA THALASSEMIA;BRUCELLA;CANCER CELL;CARDIOMYOPATHY;CD30;CHEMOKINE;CISPLATIN;COMMON CAROTID ARTERY;CRIMINAL LIABILITY;CULLING;DISEASE REGISTRY;DNA REPLICATION;DOWNREGULATION AND UPREGULATION;ECHOGENICITY;EMPA;EZETIMIBE;FASHION INDUSTRY;FAST FASHION;FLUENT;FLUOROURACIL;GENETIC ENHANCEMENT;HAZARD RATIO;HEART RATE;HYPOXIA (ENVIRONMENTAL);HYPOXIA-INDUCIBLE FACTORS;IMMUNITY;IMMUNOTHERAPY;INNATE IMMUNE SYSTEM;INTIMA-MEDIA THICKNESS;INTRACLASS CORRELATION;K-EPSILON TURBULENCE MODEL;LIPOPROTEIN;LUMINOUS INFRARED GALAXY;MACROGLOBULINEMIA;MESH GENERATION;METFORMIN;MINIMAL RESIDUAL DISEASE;MULTIPHYSICS;MUTANT;MYOPERICARDITIS;NEURONAVIGATION;NEUTROPENIA;NOISE (VIDEO);NOISE CONTROL;OPPRESSION;OVARIAN CANCER;PERIPHERAL BLOOD MONONUCLEAR CELL;POLYCYSTIC KIDNEY DISEASE;PRAVASTATIN;PRIVATE GOOD;PROGRESSION-FREE SURVIVAL;PUBLIC GOODS GAME;SETTLEMENT (FINANCE);SICKLE CELL ANEMIA;SILICON DRIFT DETECTOR;SONIC BOOM;SPECTRAL ENERGY DISTRIBUTION;STEWARDSHIP (THEOLOGY);STOCK MARKET;STORYTELLING;TELOMERE;TRANSCRIPTION FACTOR;TURBULENCE MODELING;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;WALDENSTROM MACROGLOBULINEMIA;WARFARIN;WORLD HERITAGE","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);ACUTE CHEST SYNDROME;BRENTUXIMAB VEDOTIN;BRUCELLA MELITENSIS;DIABETIC CARDIOMYOPATHY;DNA-BINDING PROTEIN;EMPAGLIFLOZIN;EPITHELIAL OVARIAN CANCER;GENOME INSTABILITY;HEART RATE VARIABILITY;IRINOTECAN;K-OMEGA TURBULENCE MODEL;LDL RECEPTOR;LYMPHOPLASMACYTIC LYMPHOMA;OXALIPLATIN;PEMBROLIZUMAB;PKD1;SEROUS OVARIAN CANCER;STIMULATOR OF INTERFERON GENES;VITAMIN K ANTAGONIST","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;SACRUM;DIABETES MELLITUS, TYPE 2;GLUCOSE;ACUTE CHEST SYNDROME;ANEMIA, SICKLE CELL;ANTIBODIES, VIRAL;BLOOD DONORS;BLOOD GLUCOSE;CELL LINE, TUMOR;CHILD;COVID-19;DNA DAMAGE;ERYTHROCYTES;FEMALE;HEART FAILURE;HEMOGLOBIN, SICKLE;HOSPITALIZATION;IMMUNOGLOBULIN G","47;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;COMPUTATIONAL FLUID DYNAMICS;EFFECTS OF NOISE POLLUTION ON HEALTH AND WELL-BEING;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HIGH-ENERGY ASTROPHYSICS AND PARTICLE ACCELERATION STUDIES;INTERDISCIPLINARY STUDY OF FASHION AND CLOTHING;AFFECTIVE GEOGRAPHIES AND MULTISPECIES ETHNOGRAPHY;ARCHAEOLOGICAL STUDIES OF ANCIENT MEDITERRANEAN CIVILIZATIONS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ASSET PRICING AND MARKET EFFICIENCY;ATRIAL FIBRILLATION;BRUCELLOSIS: A RE-EMERGING ZOONOSIS;BUILDING ENERGY EFFICIENCY AND THERMAL COMFORT OPTIMIZATION;CANCER IMMUNOTHERAPY;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CORPORATE SOCIAL RESPONSIBILITY AND FINANCIAL PERFORMANCE;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND TREATMENT OF LUNG CANCER","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;AEROSTRUCTURAL ANALYSIS;CENTRAL VENOUS CATHETERIZATION;DESIGN;ENVIRONMENTAL NOISE;EXCELLENCE;FASHION;NEUTRINO DETECTION;VALUE (MATHEMATICS);ACUTE CHEST SYNDROME;AERODYNAMIC FLOW CONTROL;AFFECT (LINGUISTICS);ANIMAL HEALTH;ANTICOAGULANT THERAPY;ARCHAEOLOGY;ARTERIAL STIFFNESS;ASSET PRICING;ATEZOLIZUMAB;ATRIAL FIBRILLATION","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;KMNETARCA SENSITIVITY;STARBURST GALAXIES;ACOUSTIC LUMINOUS;ACOUSTIC MINI-SCREENS;ACUTE CHEST;ADVANCEDMETASTATIC COLORECTAL;AGGREGATE INSIDER;ALLERGIC EPISODE;ALLERGIC MYOCARDITIS;ANCIENT GREECE;ANTI-CRIME MEASURE;ANTI-SARS-COV- ANTIBODIES;APOLLO DELPHICUS;APPLIED COMPUTATIONAL;ARCHAEOLOGICAL IMAGINATION;ARTERIAL STIFFNESS;ARTIFICIAL INTELLIGENCE;ARUMÃ- HANDICRAFT;ATRIAL FIBRILLATION;ATRIAL SEPTAL;BANK SOCIAL;BEMPEDOIC ACID;BETA DECAY;BIO-WM TRIAL;BLOOD CELL;BLOOD DONORS;BLOOD RECIPIENTS;BOARD CULTURAL;BOOM GENERATION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IVC DIAMETER;MYD LP;ADEQUATE RESPONSE;ARTERIAL STIFFNESS;COST SHARE;CELL LINES;IMMUNE CELLS;INTERQUARTILE RANGE;MM INTERQUARTILE;MYCHIGH CELLS;NSCLC PATIENTS;PATIENTS RECEIVING;RISK FACTORS;STARBURST GALAXIES;ARCA BUILDING;BILATERAL MVE;BM PB;BUILDING BLOCKS;CAMPANIA REGION;CELL VIABILITY;GENE THERAPY;HEART FAILURE;INNATE IMMUNE;KG NA;LEFT VENTRICLE;LUNG CANCER;MARKET VOLATILITY;MAYO IMAGING;MEDIAN AGE;METFORMIN ATEZOLIZUMAB","6;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",9,0.17,7,3,0,0,0,2,0,1,0,6,0,0,5.25,0,0,1,1,2.75,3,0,0,5,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1.75,381.5,5.56,1,0.25,191.75,0,0,1,0,2,0,0,1,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Ireland;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","4;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AUTOIMMUNE DISEASE;CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;GENETICS;INFLAMMATORY BOWEL DISEASE;LUNG;LUNG CANCER;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC","4;4;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL","1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","4;1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VANVITELLI",2024,39,9.05128205128205,2.05128205128205,0.384615384615385,0.384615384615385,0.512820512820513,1.14285714285714,0.9375,1.36363636363636,1.05263157894737,0.538461538461538,1,14,7,0,4,0.36,0.18,0,0.1,0.49,0.50975952503421,4.88811188811189,0.282051282051282,0.923076923076923,0.488,0.341,0.371,0.313,"GIOVANNI CIMMINO;FRANCESCO NATALE;CORRADO CARACÒ;FLORIANA MORGILLO;FRANCESCA SPARANO;CLAUDIA TROJANIELLO;ELEONORA CIOLI;PAOLO A. ASCIERTO;CARMINIA MARIA DELLA CORTE;PAOLO GOLINO;FRANCESCO PETROSINO;G. DE GREGORIO;FRANCESCO TREVISANI;MARIO FORDELLONE;DOMENICO MALLARDO;MARGARET OTTAVIANO;FORTUNATO CIARDIELLO;MATTIA BARBARINO;ANTIMO GLORIOSO;PAOLO GOLINO","8;6;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIOVANNI CIMMINO;FRANCESCO NATALE;MARIO FORDELLONE;PAOLO GOLINO;SARA FARIELLO;IRENE STRAZZERI;ROSSELLA STIGLIANI;CHIARA FUSCO;FRANCESCO PETROSINO;MATTIA BARBARINO;ANTIMO GLORIOSO;ALESSANDRO LO PRESTI;JON P. BRISCOE;MARCO ANGELILLO;ANNARITA BIANCO;ANTONELLA ROSMINO;CHIARA SCARPITTI;DANIELA PISCITELLI;CHIARA SCARPITTI;RAFFAELE LA MARCA","2.18;1.89;1.05;0.53;0.5;0.5;0.45;0.45;0.4;0.4;0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","GIOVANNI CIMMINO;ELEONORA CIOLI;G. DE GREGORIO;MARIO FORDELLONE;ANTIMO GLORIOSO;BIANCA ARIANNA FACCHINI;GIUSEPPE MINERVINI;BEATRICE LEONARDI;FRANCESCO TREPICCIONE;L. CORAGGIO;LUIGI AURELIO NASTO;DAVIDE VIGGIANO;ROBERTO PICCINOCCHI;V. NARDONE;CONCETTA TUCCILLO;ANGELO SIECZAK;GIUSEPPE VICARIO;ANTONIO VIVIANI;FORTUNATO CIARDELLO;GIOVAMBATTISTA CAPASSO","8;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIOVANNI CIMMINO;MARIO FORDELLONE;SARA FARIELLO;ANTIMO GLORIOSO;MARCO ANGELILLO;ANNARITA BIANCO;ANTONELLA ROSMINO;DANIELA PISCITELLI;CHIARA SCARPITTI;HIRA KHAN;G. DE GREGORIO;L. CORAGGIO;N. ITACO;ANTONIO VIVIANI;CORRADO CUCCURULLO;GIUSEPPE PEZZELLA;LUIGI AURELIO NASTO;CONCETTA TUCCILLO;ANGELO SIECZAK;ALESSANDRO CATTOLICO","2.18;1.05;0.5;0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.25;0.25;0.2;0.2;0.2;0.17;0.17;0.17;0.17","ALESSANDRA BELFIORE;BRUNELLA PERFETTO;CORRADO CUCCURULLO;ELENA GRIMALDI;GABRIELLA DI GIUSEPPE;GIOVANNA DONNARUMMA;GIOVANNA PADUANO;J. CHOE;MASSIMO ARIA;TRANG T. LE;VINCENZA SANSONE;ALESSANDRA DODICH;ALICE RAVIZZA;AMANY H. A. ABEED;ANDREA PANZAVOLTA;ANDREA STRACCIARI;CAMILLO MARRA;CHIARA CERAMI;COSTANZA PAPAGNO;CRISTINA FONTI","4;4;4;4;4;4;4;4;4;4;4;2;2;2;2;2;2;2;2;2","CORRADO CUCCURULLO;ELENA GRIMALDI;G. DE GREGORIO;HAFIZ KHUZAMA ISHAQ;L. CORAGGIO;LUIGI LAVORGNA;N. ITACO;ALESSANDRO CATTOLICO;ANGELO SIECZAK;ANTIMO GLORIOSO;ANTONIO VIVIANI;ENRICO POLA;FORTUNATO CIARDELLO;GIOVANNI CIMMINO;GIUSEPPE PEZZELLA;LUIGI AURELIO NASTO;MARGHERITA LUONGO;PAOLO ULISSE;SEYED HIRBOD MOUSAVI NASAB;A. CASTRILLO","4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;0","GIOVANNI CIMMINO;ANTIMO GLORIOSO;G. DE GREGORIO;ALESSANDRO CATTOLICO;ANGELO SIECZAK;ANTONIO VIVIANI;CORRADO CUCCURULLO;ELENA GRIMALDI;ENRICO POLA;FORTUNATO CIARDELLO;GIUSEPPE PEZZELLA;HAFIZ KHUZAMA ISHAQ;L. CORAGGIO;LUIGI AURELIO NASTO;LUIGI LAVORGNA;MARGHERITA LUONGO;N. ITACO;PAOLO ULISSE;SEYED HIRBOD MOUSAVI NASAB;A. CASTRILLO","7;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;COMPUTER SCIENCE;ENGINEERING;PHYSICS;BIOLOGY;PSYCHOLOGY;MATHEMATICS;CHEMISTRY;ECONOMICS;ENVIRONMENTAL SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;ART;BUSINESS;GEOGRAPHY;GEOLOGY;SOCIOLOGY","26;11;6;6;5;5;4;3;2;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;ARTIFICIAL INTELLIGENCE;IMMUNOLOGY;PATHOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;MEDICAL EMERGENCY;ACOUSTICS;AEROSPACE ENGINEERING;BIOCHEMISTRY;CARDIOLOGY;DENTISTRY;ENVIRONMENTAL ENGINEERING;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENERAL SURGERY;GENETICS;GEOMETRY;LAW;MECHANICAL ENGINEERING;MEDICAL EDUCATION;PEDIATRICS;PHARMACOLOGY;PSYCHIATRY","17;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVERSE EFFECT;CANCER;DISEASE;ALTERNATIVE MEDICINE;CHEMOTHERAPY;CLINICAL TRIAL;COMPUTATIONAL FLUID DYNAMICS;IMMUNE SYSTEM;MELANOMA;NEUROSURGERY;POPULATION;RANDOMIZED CONTROLLED TRIAL;SUPERSONIC SPEED;ACUTE KIDNEY INJURY;ADJUNCTIVE TREATMENT;ADJUVANT;ADMINISTRATION (PROBATE LAW);ANALOGY;ANTIBODY;AUDIO VISUAL;BLOOD PRESSURE;BOOM;BOTULINUM TOXIN;BYSTANDER EFFECT;CARDIOTHORACIC SURGERY;CAREER DEVELOPMENT;CERTIFICATION;CLASS (PHILOSOPHY);COGNITION;CONFIDENCE INTERVAL;CONTAMINATION;COVER (ALGEBRA);CURSE OF DIMENSIONALITY;DENTAL CARE;DIABETES MELLITUS;DIALECTIC;DIMENSIONALITY REDUCTION;DISCONTINUATION;DISJOINT SETS;DNA;EFFLUENT;ETIOLOGY;EUROPEAN UNION;EXCITED STATE;FIELD (MATHEMATICS);GENE;GINGIVITIS;GROUND MOTION;GYROSCOPE;HEALTH CARE;HEART FAILURE;HEAVY METALS;HORMONE;IMAGE (MATHEMATICS);IN VITRO;IN VIVO;INDEX (TYPOGRAPHY);INTENSIVE CARE UNIT;INVERSE;ISOSPIN;JET (FLUID);KIDNEY;KIDNEY DISEASE;LUNG;LUNG CANCER;MELATONIN;NEUROLOGY;NOISE REDUCTION;OBSERVATIONAL STUDY;OPTICAL FIBER;OUTBREAK;OXALIC ACID;PANCREAS;PATHOLOGICAL;PATTERN RECOGNITION (PSYCHOLOGY);PERCEPTION;PERIOPERATIVE;PILL;POLITICS;PRINCIPAL COMPONENT ANALYSIS;PROSPECTIVE COHORT STUDY;PSORIASIS;PSYCHOLOGICAL INTERVENTION;REDUCTION (MATHEMATICS);REFRACTORY (PLANETARY SCIENCE);RETROSPECTIVE COHORT STUDY;ROTATION AROUND A FIXED AXIS;SEX ORGAN;SOFTWARE;STAGE (STRATIGRAPHY);STIMULATION;STROKE (ENGINE);SUBCLINICAL INFECTION;SUBJECTIVITY;SYMMETRY BREAKING;THYROID;TRANSCRANIAL DOPPLER;TRANSPLANTATION;URIC ACID;VACCINATION;VIRUS;VISUAL ANALOGUE SCALE;VOCATIONAL EDUCATION;VOLCANO;WETLAND","4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADENOCARCINOMA;AIRCRAFT NOISE;BEVACIZUMAB;BIOREMEDIATION;BREAST CANCER;CHICKENPOX;COGNITIVE IMPAIRMENT;COLORECTAL CANCER;COMPLETE RESPONSE;DEMENTIA;DEMOCRACY;EJECTION FRACTION;ENVIRONMENTAL REMEDIATION;EUTHYROID;GENE EXPRESSION;HAZARD RATIO;INNATE IMMUNE SYSTEM;JET NOISE;LYMPHOCELE;MEASLES;NEURORADIOLOGY;NOISE (VIDEO);OPEN SOURCE;PANCREATIC CANCER;PERIOPERATIVE NURSING;PHASES OF CLINICAL RESEARCH;PHRAGMITES;PHYTOREMEDIATION;PINEAL GLAND;PITUITARY GLAND;PLACEBO;POLYPILL;PROTOCOL (SCIENCE);RESIZING;REYNOLDS-AVERAGED NAVIER–STOKES EQUATIONS;SAGNAC EFFECT;SEROLOGY;SONIC BOOM;SPASMODIC DYSPHONIA;SUBGROUP ANALYSIS;TOLERABILITY;VASCULAR RESISTANCE;VISUAL PERCEPTION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DEMOCRATIZATION;DOUBLE BLIND;GENE SIGNATURE;HYPOPHYSITIS;PANCREATIC DUCTAL ADENOCARCINOMA;RUBELLA;SEROPREVALENCE;TRIPLE-NEGATIVE BREAST CANCER","1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;ADOLESCENT;MIDDLE AGED;ADULT;AGED;AGED, 80 AND OVER;ANEMIA, SICKLE CELL;ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;ANIMALS;BIODEGRADATION, ENVIRONMENTAL;CANNABIDIOL;CARCINOMA, PANCREATIC DUCTAL;CARDIOVASCULAR DISEASES;CELL LINE, TUMOR;CELL PROLIFERATION;CELL SURVIVAL;CERTIFICATION","31;7;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","THEORETICAL AND EXPERIMENTAL NUCLEAR STRUCTURE;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;AEROACOUSTIC ANALYSIS OF JET NOISE;CHALLENGES AND APPLICATIONS OF DETONATION PROPULSION TECHNOLOGY;CHEMOMETRICS IN ANALYTICAL CHEMISTRY AND FOOD TECHNOLOGY;DEVELOPMENT AND IMPACTS OF ENERGY INTERNET;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS;ENVIRONMENTAL IMPACT OF HEAVY METAL CONTAMINATION;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;ETHICAL IMPLICATIONS OF NEUROENHANCEMENT TECHNOLOGIES;FOOD TOURISM AND GASTRONOMY RESEARCH;GENDER BIAS IN BIOMEDICAL RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HERNIA REPAIR TECHNIQUES AND MATERIALS;IMPACT OF COVID-19 ON DENTAL PRACTICE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";ACNE INVERSA;ACOUSTIC HOLOGRAPHY;ACOUSTIC METAMATERIALS;ADJUNCTIVE TREATMENT;ADVERSE DRUG EVENTS;AEROACOUSTICS;AIRCRAFT NOISE;AUDIO VISUAL;BOUNDARY LAYER CONTROL;BYSTANDER EFFECT;CANCER TREATMENT;CARDIOTHORACIC SURGERY;CAREER DEVELOPMENT;CFD SIMULATIONS;CHICKENPOX;COMPLETE RESPONSE;CT SCREENING;CURA;DEMENTIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR DISEASES;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;ACID-TREATED IPHRAGMITES;ACOUSTIC ANALOGY;ACQUIRED MILD;ACUTE KIDNEY;ADJUNCTIVE TREATMENT;ADJUVANT SETTING;ADVERSE EVENTS;ANALOGY APPROACH;ANALYSIS DMCA;ANALYSIS DPCA;ANGIOTENSIN-CONVERTING ENZYME;ANTI-TUMOUR INNATE;ANTIPROTEINURIC EFFECT;AORTIC REGURGITATION;ARTERIAL RESISTANCE;ARTIFICIAL INTELLIGENCE;AUDIO-VISUAL STIMULI;AUSTRALISI WETLANDS;BIBLIOMETRIC DATA;BREAST CANCER;CAMPI FLEGREI;CANCER PATIENTS;CANCER TREATED;CAREER DEVELOPMENT;CARERT RESULTS;CELL DISEASE;CFD METHODOLOGY;CHEMORT PRELIMINARY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FTDTPI BEV;ENDOTHELIAL CELLS;DIABETIC PATIENTS;LUNG CANCER;PROXIMAL TUBULE;SYSTEMATIC REVIEW;TUBULE CELLS;AGED LT;CELL LINES;FTDTPI MONOTHERAPY;GLIFLOZIN TREATMENT;HR CI;IMMUNE RESPONSE;INNATE IMMUNE;LOGISTIC REGRESSION;MITOCHONDRIAL CONTENT;SCLC CELL;STAGE III;SUBGROUP ANALYSIS;THORACIC SURGERY;TRAINEE OBSTETRICIANS;ACR REDUCTION;ADDUCTOR-TYPE SD;ADVANCED TECHNOLOGIES;ADVANCED TECHNOLOGY;AGE SEX;ARTIFICIAL INTELLIGENCE;BLOOD PRESSURE;CANCER PATIENTS;CARDIAC IMAGING","7;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
